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CHAPTER I 
INTRODUCTION 
Since the discovery of nicotinamide as one of the 
hydrolysis products of coenzymes I and II (1, 2) and the 
finding that nicotinic acid and nicotinamide were active 
in the cure and prevention of canine blacktongue (3, 4) 
and human pellagra (5, 6), the metabolism of these com-
pounds has been extensively studied. Five urinary metabo-
lites of niacin have been isolated and identified in 
mammalian species. These are N1 -methylnicotinam.ide_, 
nic·otinamid4t-N:..oxide, ·· N1 -metbyl-2-pyridone-5-carboxamide , 
N1 -methyl~4-pyridone~3-carboxamide ab.d . nicotinuric acid. 
These same ·metabolites ·are fbrmedfrom both nictonic acid 
and nicotinamide although the proportion differs with t he 
compound administered and the size of the injected dose. 
The biosynthesis of nicotinamide adenine dinucleotide 
from these vitamins has also been well established (7). 
In recent years, Greengard and coworkers (8) reported that 
hypophysectomy before administration of nicotinamide 
r esults in an increase of both the degr~e and duration of 
'· the el evated NAD~ concentration in liver. Further stud-
ies have established that the pituitary gland may regulate 
... 
NAD+ biosynthesis through its control of the thyroid and 
1 
2 
adrenal glands (9). The same workers also reported that 
nicotinamide deamidase activity in the liver also was in-· 
creased by hypophysectomy and that the rate of the excre-
tion of injected nicotinamide in hypophysectomized rats 
was much slower than that in normal rats (10). From these 
results, they concluded that the increase in nicotinamide 
deamidase activity was responsible for the increase in the 
duration of the elevation of NAD+ concentration which fol-
lows the administration of nicotinamide. However, there 
should be other factors which effect the NAD+ concentra-
tion in hypophysectomized rats, because the injection of 
nicotinic acid and tryptophan also resulted in an increased 
of NAD+ concentration in hypophysectomized rats (11). If 
the effect of hypophysectomy on NAD+ bisynthesis is to in-
crease nicotinamide deamidase activity in liver, then 
there should be no effect on increasing NAD+ e,oncentration 
in hypophysectomized rats by injection of nicot:i.nic acid 
or try:ptophan, because nicotinamide deamidase is not in= 
volved in the biosynthesis of NAD+ from these compounds 
(12). 
This dissertation will report investigation of possi-
ble factors which may control the NAD+ concentration in 
hypophysectomized rats by comparison of the differences in 
normal and hypophysectomized rats on the excretion of 
radioactivity in the urine following intraperitoneal in-
jection of different levels of nicotinic acid-7-14c and 
nicotinamide-7-14c by studying the metabolism of these 
3 
radioactive vitamins in the liver at short times after 
intraportal injection. During the course of these stud-
ies, two new urinary metabolites of nicotinic acid and 
nicotinamide in normal and germ free rats were discovered, 
isolated, and identified. 
CHAPTER II 
LITERATURE REVIEW 
Historical 
Nicotinic acid was first synthesized in 1867 by Huber 
(13) by oxidizing nicotine with sulfuric acid and 
potassium dichromate. However, he only knew the compound 
had the formula c5H5No 2 at that time, and he did not rec-
ognize it as pyridine carboxylic acid until 1870 (14)o 
The term "nicotinic acid" was first used by Weidel (15), 
. 
who by the oxidation of ni'cotine with nitric acid produced 
a compound which he assumed to have the composition 
c10H8H2o3 o Later, Laiblin (16) showed that this compound 
was·pyridine carboxylic acid and it was identical to the 
compound made by Huber. In 1879,Weidel (15) produced the 
same compound from ~-p·icoline and, thus, demonstrated that 
nicotinic acid is pyridine-3-carboxylic acid. 
Almost fifty years elapsed before n:fcotinic acid was 
isolated from natural products. Suzuki, Shimamura, and 
Odake (17) isolated the compound from rice branc Funk 
(18) isolated nicotinamide from both yeast and rice 
polishings during the search for the antiberiberi factor~ 
thiamine, but found the compound had no activity in curing 
pigion beriberi, so its biological role in nutrition was 
4 
5 
at first neglected. Willamn (19), in 1917, impressed by 
the common occurrence of nicotinic acid and the anti-
neuritic vitamin in several natural substances, tested 
nicotinic acid and trigonelline, as well as other pyridine 
derivatives, for antineuritic potency but found that none 
of them caused any permanent improvement in polyneuritic 
fowls. Szymanska and Funk (20) attributed appetite-
stimulating and weight-preserving action to nicotinic acid 
and the amide. 
In 1934, Warburg and Christian (1) isolated nicotina-
mide from coenzyme II and demonstrated its function as a 
part of this hydrogen transferring coenzyme (21). Shortly 
thereafter, Euler, Alberts, and Schlenk (2) obtained nico-
tinamide from coenzyme II, and it was shown that both 
coenzymes were nicotinamide adenine dinucleotide, but that 
coenzyme II contained three molecules of phosphoric acid 
while coenzyme I contained two. Kuhn and Vetter (22) also 
isolated nicotinam.ide from heart muscle. These studies 
stimulated further interest in the possible nutritional 
significance of nicotinic acid and its amide. In 1936, 
Funk and Funk (23) found a large food intake and better 
growth in rats and pigeons on certain diets when given the 
acid and especially the amide. Frost and Elvehjem (24) 
also observed a growth stimulus from nicotinic acid when 
fed with adenylic acid to rats on purified diets. In 
1937, Koeln and Elvehjem (25) isolated nicotinic acid and 
its amide by fractionating a liver extract and showed 
6 
\· . :,· ·,' \. . : 
these compounds have a marked antf-blacktongue activity in 
I '' 
dogs. The activity of nicotinic acid in the treatment of 
blacktongue was soon verified by a number of workers (3, 
4, 25). The beneficial effects of nicotinic acid on 
pellagrins was reported by Spie tl ?-1. (5), by Harris (6), 
and by Smith (27). 
Effect of Nicotinic Acid Deficiency in the 
Human and Dogs 
Among the mammalian species, oniy the dog and human 
develop syndromes characteristic of a deficiency of nico-
tinic acid. In other species, this deficiency state is 
not easily differentiated from other nutritional 
deficiencieso 
In the dog, a deficiency of nicotinic acid results in 
the syndrome described as canine blacktongue (28)o The 
animal in this state has no appetite for food or water~ 
oral manifestations such as lesions on the inner surfaces 
of the gums., lips., and cheeks develop 9 and the tongue 
assumes a bluish-black c.olor <29). The, ner:ves if1- tl:;J.e area 
. i . . 
of these lesions degenerate, and extensive histjblogical 
'I 
changes take place in the spinal cord and other regions of 
the nervous system (309 31). 
In the hum~n~·· a deficiency of nicotinic acid is 
designated as pellagra. The early clin!cal signs of 
deficiency include weakness, lassitude, indigestion. and 
anorexia, usually followed in the course of several months 
7 
by dermatitis, diarrhea, dementia, and finally death (32). 
Body lesions are usually found in areas most subject to 
mechanical irritation or body secretion. The mental symp-
toms usually include irritability, headaches, sleepless-
ness, and the loss of memory. Emotional instability is 
usually an early sign of pellagra, and advanced cases may 
develop acute delirium. Nicotinamide is preferred over 
nicotinic acid as therpeutic agent because of better tol-
erance. It is used in 50 mg oral doses ten times daily 
for the treatment of the various stages of the human 
pellagra syndrome and for overcoming toxicity symptoms 
incurred during sulfonamide therapy. 
The specific requirement for nicotinic acid in man 
has been difficult to assess for many reasons, but a 
qaily dietary intake of less than 7 mg of nicotinic acid 
is usually associated with pellagra (33)~ The presently 
accepted value was calculated on the basis of body weight 
and caloric intake, and finally by increasing the value 
by a 50% safety factor . The recommended daily dietary 
allowance has been set at 18-21 mg equivalent for men, 
17 mg for women, and 6-17 mg equivalent for children. 
Adult dogs and puppies require 200 to 235 µg per kg of 
body weight per day, respectively (34). 
Preparation and Properties 
Nicotinic acid was commercially prepared by oxidation 
of pjcoJine or nicotjne witlJ nitric acid, potassium 
8 
dichromate, potassium permanganate, etc., as oxidizing 
agents (13, 15, 35, 36) in earlier times,but now these 
oxidizing agents have been replaced by air in the vapor 
phase using a vanadium iron oxide (37). Ciba (38) uses 
the air oxidation of picoline or quinoline in the vapor 
phase with vanad1um pentaoxide-sulfuric acid catalyst on 
silica ge J to produce nicotinic acid. ~-picoline also 
can be oxidized by means -of sulfuric acid in the presence 
of a se l enium compound (39). Nicotinamide was prepared by 
partial hydrolysis of 3-cyanopyridine ( 40) with base in 
the presence of hydrogen peroxide. 3-Cyanopyridine was 
prepared by treating pyridine with bromine and bydrobromic 
acid to yield the dark red perbromide; this, when heated 
with cuprous cyanide at 170°0 is converted into 
3-cyanopyridine (41). 
Nicotinic acid forms white needle-like crystals, of 
molecular weight 123, which melt at 235-237°0. It is 
slightly soluble in cold water and ether, but soluble in 
hot water and alcohol. It behaves as both a base and an 
acid, forming salts with either inorganic acids or with 
metals .ions. Nicotinic acid also reacts with alkyl 
halides to form quaternary nitrogen substituted compounds. 
Nicotinamide is a white substance, which crystallizes 
from benzene in needles, m.p. 131°C. It is very soluble 
in water, 95% alcohol and in glycerol but only slightly 
soluble in ether. On distillation with phosphorous 
pent oxide, it yields 3-cyanopyridine and on hydrolysis 
9 
with acid or alkali it yields nicotinic acido On heating 
in a very dry tube, pryidine is evolvedo It can also form 
N-alkyl compounds of the pyridine nitrogen with alkyl 
halideso 
Biosynthesis of Nicotinic Acid and Nicotinamide 
The relationship of nicotinic acid and tryptophan in 
a number of organisms is well establishedo In 1945 9 Krehl 
(42) observed that tryptophan supported the growth of 
niacin-deficient ratso Additional studies revealed that 
addition of tryptophan to the diet resulted in an increase 
in the excretion of N1-methylnicotinamide in the urine 
(43, 44). A number of nutritional studies have shown that 
tryptophan can replace nicotinic acid in the rat, dog 9 
rabbit, pig, monkey, chick') and in humans (45, .46, 47') 48)o 
Studies with mutant strains of Neurospora crassa (49, 50) 
"' 
and with mammal s have shown that the pathway- from 
tryptophan proceeds through kynurenine (51), 3-hydroxy-
kynurenine (49), 3-hydroxyanthranilic acid (52, 53, 54) , 
an unstable intermediate, and quinolinic acid (see Figure 
l)o Further evidence for the metabolic relationship be-
tween tryptophan and niacin has come from a study of the 
metabolism of tryptophan labeled with isotopes at various 
positions in the molecule (55) o The results indicated 
that position 3 of the indole ring becomes the carboxyl 
carbon of niacin (55 , 56, 57, 58) and that the. nitrogen 
of the indole ring is converted to the pyridine ring 
10 
nitrogen of niacin (59, 60). 3-hydroxyanthranilic acid 
is now well established as an intermediate in the conver-
sion of tryptophan into·nicotinic acid. Thus, it can 
replace tryptophan in promoting the growth of rats (61, 
62), but it appears to be converted into quinolinic acid 
and not nicotinic acid by rat liver slices (60, 63). In 
1951, Priest et al. (64) reported that a soluble enzyme 
system from liver and kidney catalyzes the conversion of 
3-hydroxyanthranilic acid to quinolinic acid. Several 
investigators subsequently showed that the primary ·Droduct 
of oxygenation reaction was probably 2-amino-3-acroleyl 
fumaric acid and the cyclization of the later resulted in 
the formation of quinolinic acid (65, 66, 67, 68). 
Nishizuka and Hayaishi (69) described an enzyme sys-
tem from rat liver which converts 3-hydroxyanthranilic 
acid to nicotinic acid ribonucleotide, when supplemented 
with 5-phosphoribosyl-1-pyrophosphate. Nicotinic acid 
ribonucleotide is converted to desamido-NAD in the presence 
of ATP by pyrophosphorylase, and this compound is then 
amidated to form NAD+ in the presence of glutamine and ATP 
by NAD+ synthetase (70, 71). The metabolic pathway which 
leads from tryptophan to the synthesis of NAD+, which is 
now known as the 8'NAD+ pathway of tryptophan 11 is shown in 
Figure 1. NAD+ can be degradated by diphosphopyridine 
nucleotidase (NADase, E,C,3.2.205) to nicotinamide and 
adenosine diphospha.teribose (72, 73, 74). 
Although mammals and Neurospora are able to convert 
Figure 1. Metabolism of Tryptophan Leading to Formation 
of Nicotinic Acid and Nicotinamide 
1. Tryptophanpyrolase (EC 1.1.3.12); 
2. Kynuenine formylase (EC 3.5.1.9), 
3. Kynurenine-3-bydroxylase (EC 1.14.1.2); 
4. Kynureninase (EC 3.7.1.3); 
5. 3-hydroxyanthranilic acid oxidase 
(EC 1.13.1.6); 
6. Spontaneous; 
7. Quinolinate transribosylase; 
8. Desamido-NAD pyrophosphorylase (EC 2.7.7.18); 
9. NAD+ synthetase (EC 6.3.5.l); 
10. NAD+ glycobydrolase (EC 3.2.2.5); 
11. Nicotinamide deamidase. 
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tryptophan to nicotinic acid yia the biosynthetic pathway 
shown in Figure 1, evidence has accumulated that in 
bacteria and higher plants the biosynthesis of nicotinic 
acid is accomplished by a different pathway. Volcani and 
Snell (75) demonstrated .. that kynurenine and 
3-hydroxyanthranilic acid,both of which are intermediates 
in the tryptophan pathway,could neither replace nicotinic 
acid as a growth factor for a member of nicotinic acid 
requiring species of bacteria nor enhance the growth 
response of these bacteria to suboptional amounts of 
nicotinic acid. Stainer and Tsuchida (?6) found that 
Psudomanas species adapted to growth with tryptophan as 
the sole carbon source lacked the enzyme needed for the 
oxidation of 3-hydroxyantbranilic acid and, thus, appears 
to be unable to form nicotinic acid from tryptophan.T, It 
has been shown (77, 78~ 79) that some microorganism can syn-
thesize nicotinic acid fr9m carbon sources other than 
tryptophan. Ortega and Brown (80) have shown that 
nicotinic acid could be synthesized in yiY.Q in~· coli from 
a 3 carbon.compound (glycerol or a glucose metabolite) and 
a 4 carbon dicarboxylic acid. Other studies with Bacillus 
subtilis (81) and M. tuberculosi~ (82) indicated that both 
aspartate and glycerol could serve as precursors of 
nicotinic acid 'in these organisms. Isqui th and Moat (78) 
found that crude extracts of Clostridum butylicum were 
able to incorporate uniformly 14c labeled aspartate and 
glycerol in the same manner as did growing cultures. 
Hov,rever, upon fractionation of the extract, only ate~ 
acetyl-coA and formate gave rise to nicotinic acido 
Chandler et alo (83) reported that cell free pre:parations 
f 1 . b 14n d l o·· E:. c:;~ are a le to convert aspartate= v an glycero 
, 
to quinolinic acido Degradation of the product formed 
from uniformly labeled aspartate-14c showed that the 14c 
was incorporated into carbons 2, 3, 7, and 8 of 
quinolinate. 
MetaboliE,rn of Nicotinic Acid and .Nicotinamide 
UriJ1ar;y_J1etaboli teE,_ .. _of_)~ico.tinic Acid 
and N~cotinarnide 
-----..-,,~-~-,,~·-··~-,---.............. _,_ ......... ____ _ 
The earliest attem:pts to study the fe.te of ingested 
nicotinic acid and nicotinamide were confined to isolation 
and identification of various metabolites in different 
animals species (8L~-88) o In add.i tion to the acid form and 
annde form of the tamin 9 the presence of N 1 -
inamide-N-o:xide ( 91) , N'-meth;yl-LJ--pyridone-
c oxamide C 92, 93) 9 J\T' -~methyl-2-pyridone-5-carboxamide 
( 9L:-) have been reported in the urine of various mammalian 
s:9ecies, and <linicotin;ylornithine in the chick (95) o 
Nicotinuric acid is a major urinary metabolite of' 
nicotini.c acid after nicotinic acid is administered to 
animals. It is formed from nicotinic acid by conjugation 
i.d th glycine. 
15 
This compound constitutes about 60% of tertiary 
nitrogen derivatives.of nicotinic acid excreted by normal 
' ~·\' 
rats'j' but forms a much lower proportion. in the case of 
' :~l'··':~'\t.if ~-
pant o the ni c acid deficient rats (94)o This suggested that 
coenz;yme-A is involved in the biosynthesis of nicotinuric 
acido 
The excretion of N1-methylnicotinamide in the urine 
was first noted by Najjar and his coworkers (89 9 90)o 
They observed that pellagrins_excreted a substance in the 
urine which fluoresced when treated with strong alkalio 
This substance-~- designated as F 1 9 disappeared when the 
patients were treated with.nicotinic acid and was replaced 
by another fluorescent substance.known as F2o F2 is not 
present in the urine of pellagrinso The administration. of 
r 
nicotinie acid to a normal .. individual led to a marked in-
crease in the excretion of this second fluorescent sub-
stanceo They found that in addition to nicotinic acid, 
,\.: 
nicotinamide i and coramine were able to bring to about 
:ft 
this transformation~ but not trigonelline9 quinolinic acid 
or pyrazine-carboxylic acido The e.xcretion of F 1 was also· 
observed-in dogs with cani:p.e blacktongue; it was replaced 
by F2 wh~n dogs we;r:-~r given nicotinic acid (96) o Large 
doses of F2 were excreted by all animals capable of 
methylating nicotinamide. In rats, which synthesize 
16 
nicotinic acid from tryptophan, F 2 was isolated and shown 
to be N1-methylnicotinamide by comparison with the known 
compound which synthesized by the method of Karrer et_ 
(97)o 
Both compounds formed a picrate, M.P. 189.5°0 (96, 9?). 
Nicotinamide was converted into N1-methylnicotinamide by 
incubation with rat liver slices, and the extent of the 
transformation was increased by the addition of methiori.ine 
(98). Ellinger (99) showed that kidney and muscle did not 
methylate nicotinamide, the enzyme being present only in 
liver. Moreover, the enzyme was specific for nicotinamide, 
and did not methylate nicotihic acid. Liver tissue from 
rats 1.rvith a low N1-methy1nicotinamicle elimination was only 
1 
able to convert small amounts of nicotinamide into N-·--
methylnicotinamide, the addition of methionine increased 
the amount farmed. An enzyme system, which was partiall;y 
purified, was isolated by Cantoni (100) and shown to 
synthesize N1-methylnicotinamide anaerobically from 
methionine and nicotinamide in the presence of magnesium 
ions and an energy, ATP. The enzyme was named nicotina-
mi.de methylkinase. The methionine and adenosine tri-
phosphate form S-adenosyl-methionine before the transfer 
of the methyl group to nicotinamide. N1-methylnicotinamide 
17 
is not the end metabolite of nicotinic acid and nicotina-
mide, it can be further oxidized in yivo to corresponding 
pyridone. This was demonstrated by Knox and Grossman (93) 
who isolated an unknown nicotinamide metabolite and iden-
tified it as N1-methyl-6-pyridone-3-carboxylamide (N1= 
metbyl-2-pyridone-5-carboxamide). 
It was biologicall~ synthesized from N1-methynicotinamide 
by quinine-oxidizing enzyme of rabbit liver (92, 93) and 
chemically synthesized by oxidating N1-methylnicotinamide 
with alkaline ferricyanide (101). Another nicotinic acid 
and nicotinamide metabolite also formed by oxidation of 
N1-methylnicotinamide and which is present in rat urine in 
substantial amount has been identified as N1-methyl-4= 
pyridone-5-carboxamide (94). 
0 
II CONH Q2 
3 
It has since been identified in human urine and monkey 
urine (94), and in human plasma (102). The enzyme which 
oxidizes N1-methylnicotinamide to both N1-metbyl-4= 
pyridone-3-carboxamide and N1-methyl-2-pyridone-5= 
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carboxamide was isolated from hog liver (103). Purifica-
tion studies of this enzyme have shown that the formation 
of these two pyridones is catalyzed by the same enzyme 
(104). This enzyme has similar properties to these which 
were reported for rabbit liver aldehyde oxidase. The 
ratio of the 6-pyridone to the 4-pyridone were varied 
among different animal species, but the ratio was constant 
for a given species. 
Another urinary metabolite of nicotinic acid and 
nicotinamide is nicotinamide-N-oxide. 
rrhis compound was reported by Chaykin et al. ( 105) in rat 
ver after injection of nicotinamide. It is also an 
excretory product of nicotinamide in the mouse (103, 106). 
rrhe formation of nicotinamide-N-oxide is reversible since 
it could be reduced to nicotinamide in hog liver (105). 
'11he enzyme system which reduced nicotinamide-N=oxide to 
nicotinamide was isolated from hog liver and purified 280 
fold (106). The reduction was dependent on the presence 
of NADH or a low molecular weight constituent found in 
boiled liver supernatant. The reaction was as follows: 
H7 + NADH + Nicotinamide-N-oxide ~ NAD + Nicotinamide 
. , 
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The purified enzyme b,as the spectrum of a metalloflavo-
protein and has xanthine oxidase activity. Milk xanthine 
oxidase also catalyzed the nicotinamide-N-oxide reduction 
reaction (107). This evidence led to the proposal that 
xanthine oxidase. is responsible for nicotinamide-N-oxide 
react'ion. The nicotinamide-N-oxide oxygen is transferred 
to xanthine by xanthine oxidase (108). 
Quantitative studies of the excret.ion of nicotinic 
acid and nicotinamide metabolites in the urine have demon-
· strated that the metabolites vary with anima_l species~ 
age, diet 9 and the dosage of vitaminq 
; •. ,.1,1 
The fc~~ier meth-
.. 'I 
ods used for estimB;~ing trigonelline i.nvolved hydrolysis 
·., 
to nicotinic acid with strong alkali, so that in earlier 
studies N1-met~lnicotinamide was included in the value 
reported for trigonelline (109)0 More complete data on the· 
·urinary excretion of nicotinamide, nicotinic acid and 
their metabolites were provided by Elinger et al. (87). 
Although they did not estimate N1-methyl-2-pyridone-5= 
carboxamidej they found in contrast to the claims made by 
many earlier workers that no trigonelline· or nicotinuric 
'1 ; ' 
was excreted by man~ rat, cat,. guinea. pig or rabbit on 
normal diet. Quantitative studies of the excretion of 
nicotinic acid and its amide metabolites in the urine of 
various animal species have been greatly improved by the 
introduction of chromatographic techniques and the use of 
radioactive nicotinic acid and nicotinamide tracers. 
In the human, Reddi and Kodicek (110) reported that 
• 
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normal adults excreted 0.5-0.6 mg of N1-methylnicotina-
mide and 0.2-0.3 mg of tertiary nicotinyl derivative o:f 
nicotinic acid in the urine each 3 hours. When 100 mg of 
nicotinic acid were given orally to normal adults, 6-15 mg 
of N1-methylnicotinamide and 2.8 mg to 5.7 mg nicotinuric 
acid were excreted in the urine each 3 hours. When 100 mg 
o:f nicotinamide were administered orally to normal adults, 
7 to 17 mg of N1-methylnicotinamide and 2.8 to 5.7 mg of 
nicotinamide were excreted into the urine each 3 hours. 
The most complete data on the excretion of urinary 
metabolites of nicotinic acid and nicotinamide in the rats 
(111) and mice (103) following the injection of various 
levels of nicotinic acid and nicotinamide was reported by 
Greengard ~ al. and Chaykin et al., respectively. In 
addition to injected nicotinic acid .and nicotinamide, five 
urinary metabolites have been reported. These are 
N1-methylnicotinamide, nicotinuric ·acid, nicotinamide-N-
oxide, N1-methyl-2-pyridone-5-carboxamide and N1-methyl-4-
pyridone-3-carboxamide. The percentage of each metabo-
lite in the urine differs with the compound administered, 
the size of injected dose and species of animal (103~ 110, 
111). 
Metabolism of Nicotiamide Adenine Dinucleotide 
Structure Determination 
Diphosphopyridine nucleotide (the original name of 
NAD'1·) waD isolated from brewer I s or baker's yeast by 
fractional precipitation followed by chromatography. Its 
structure was elucidated by degradation. Acid hydrolysis 
cleaved the substance into one molecule of adenine, two 
.molecules of D-ribose-5-phosphoric acidJ and one molecule 
of nicotinamide (112). Mild alkaline hydrolysis yielded 
an adenosine-diphosphate ribose compound, and nicotinamide; 
vigorous alkaline hydrolysis yielded adenosine diphoE,phate. 
Enzymatic hydrolysis yielded adenosine and nicotinamide 
riboside (113)0 Consequently, the structure proposed for 
coenzyme I consisted of one molecule of adenosine and one 
molecule of nicotinamide riboside linked through the 
5',-position by pyrophosphate group. 
I:5.io~pt;;hesis of Nicotinamide Adenine 
Dinucleotide 
The biosynthesis of NAD'll' from nicotinic acid or its 
amide was generally accepted at first to proceed from 
nicotinamide mononucleotide. Later, it was suggested that 
alternative metabolic pathways might exist f9r the syn-
' 
t;h(3SJ_s of NAD"' from nicotinic acid or nicotinamide o Now 9 
it appears that a pathway common to many species exists 
for the biosynthesis of NAD+ from nicotinic acid mono-
nucleotide via desamido-NAD;. There are at least two path-
ways leading to the formation of nicotinic acid 
mononucleotide; from nicotinic acid and quinolinic acid. 
The reaction which converts quinolinic acid to nicotinic 
acid mononucleotide is catalyzed by quinolinate 
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phosphoribosyltransferase (decarboxylation) in the pres-
ence of 5-phosphoribosyl-1-pyrophosphateo Quinolinate 
phosphoribosyltransferase is a key enzyme in the uNAD+ 
pathway of tryptophan metabolism 01 and the 11 aspartate path-
way." The highly purified enzyme was isolated from beef 
liver (112, 113) and a Psudomonad (114). Gholson g:t; al. 
demonstrated that this enzyme differs from nicotinic acid 
mononucleotide pyrophosphorylase (nicotinate phosphoribosyl 
transferase)o They -also showed that the total activity of 
the enzyme forming nicotinic acid mononucleotide from 
quinolinic is almost 20 times that of the enzyme forming 
this compound from nicotinic acid in acetone powder 
extract of liver. The pathway for the synthesis of NAD+ 
from nicotinic acid was proposed by Priess and Handler 
(70, 71), who established nicotinic acid mononucleotide 
and desamido-NAD as intermediateso This pathway is known 
as the Priess-Handler pathway. The enzyme which catalyzes 
the formation of nicotinic acid was partially purified 
from erythrocytes and beef liver acetone powder (116). 
Recently,Smith and Gholson (lJ.7) have purified nicotinic 
., . 
acid phosphGribosyltransferase from bovine liver. Kinetic 
studies of this enzyme indicated ATP is not a required 
substrate for bovine liver nicotinate phosphoribosyl-
' 
transferase, as has been're:ported, but activates the 
enzyme by lowering the apparent Michaelis constant for 
both nicotinic acid and 5~phosphoribosyl-l~pyrophosphate 
- ·,·~: 
by 10 foldo ·· The kineti<;s of ATP activation indicate that 
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ATP is binding at only one site on the enzymeo When ATP 
is present in the reaction, it is cleaved to formed ADP in 
an amount approximately stoichiometric with nicotinic acid 
mononucleotide formationo It is suggested that ATP 
cleavage may be re.quired for the activation of the enzyme o 
It has been known for many years that nicotinamide is 
an adequate form of the vitamin for meeting the general 
mammalian dietary requirement for the precursors of the 
nico tinami.de coenzymes. . In general, nicotinamide is 
first deamidated by nicotinamide deamidase to nicotinic 
acid. The later then enters into Priess-Handler pathway 
+ 
for NAD synthesis. Nicot.inamide is the predominant form 
of the vitamin in the blood and other mammalian tissues 
(118). In contrast to the finding with many nicotinamide 
utilizing micro9rganis~s, the ability to convert nicotina-
mide to nicotinici acid is a property possessed by few 
mammalian cells (119). The question of how mammalian 
cells lacking nicotinamide deamidase can utilize nicotina-
mide is a problem of long standing. Even in liver where 
the deamidase has been found (120), the problem has only 
been partially resolved. This.deamidase has attracted 
considerable interest because.its activity is masked in 
. . 
tissue homogenate. by an endogenous inhibitor •. Greengard 
and coworkers (121) have suggested.that this phenomenon 
., :+ 
offers a means for control of NAJ;) biosynthesiso However, 
.. 
there is stil'l some question regarding the physiological 
1·•f 
role of this enzyme. Its Km valuelfor nicotinamide 
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(4 x 10-a to 2.5 x 10- 1 1':']:) (11, 119) is rather high in the 
light of the very low concentration of nicotinamide 
(5 x 10- 5 to 10-6M) normally found in mammalian cell (122). 
This may not be a cause for concern since the quantities 
of NAD+ synthesized are.ordinary quite small and the 
enzyme and substrate could be compartmentalized. Another 
difficulty is that the homogeneous nicotinamide deamidase 
obtained from rabbit liver microsomes has considerable 
esterase activity (123). It does show a preference for 
the pyridine ring in both its amidase and esterase activ-
ities, but this does not prove that it functions physio-
logically as nicotinamide deamidase. There is cause for 
further evaluation. Ha:yaishi et al. (124) have recently 
suggested that nicotinamide administered by intraportal or 
intraperitoneal injection first passes into the intestine 
and is deamidated there and then is transferred to the 
• liver for synthesis of NAD+ through the Priess-Handler 
pathway. 
The discovery by Dietrich et al. (125, 126) of the 
widespread occurre~ce of ~pacific nicotinamide ribo-
nucleotide pyrqphosphorylase has raised the possibility of 
yet another pathway by•which nicotinamide might be con-
verted to' NAD;. This .. pathway can permit the utilization of 
nicotinamide without deamidatlon. Grunnicke et al. (122) 
hav'~,; reported evidence which is compatible with this 
latter pathway being the predominant one in Ehrlich tumor 
cells maintainedat:physi6logical concentrations of 
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nicotinamide (5 x 10- 6 1'1)., and Greenbaum (127) has also 
shown that this pathway is predominant in mammary tissueo 
A summary of the pathways leading to NAD+ is.shown in 
Figure 2. 
Triphosphopyridine nucleotide (TPN+, coenzyme II) 
TPN+ was isolated from hemolyzed horse erythrocytes ( 21) 
and its structure was elucidated by degradation (128, 
129). Cleavage of TPN+ by nucleotide phosphatase yielded 
nicotinamide mononucleotide and a compound established 
later as adenosine 2 1 5 1 diphosphate. Selective hydrolysis 
of the 5'-phosphate group of the diphosphoadenosine frag-
ment yielded adenosine 2'-phosphate. This structure 
assignment was based on a comparison of the monophosphate 
with adenylic acid. TPN+ 'i.s synthesized by enzymic 
phosphorylation. An enzyme was obtained from yeast that 
catalyzed the synthesis of the dinucleotide phosphate from 
dinucleotide by direct phosphorylation with adenosine 
triphosphate in the presence of magnesium of: manganese ion 
(129). 
The Pyridine Nucleotide Cycle 
. 
It has been long known that nicotinamide is a degra-
dation product of nicotinamide adenine dinucleotide formed 
by NAD glycoh;ydrolase (EC 3.2.2.5) and that the part of 
the nicotinamide formed in this way can be reutilized by 
conversion to nicotinic acid by nicotinamide deamidase and 
then converted to NAD+ via the Priess-Handler pathway 
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Adenine Dinucleotide and the 
Pyridine Nucleotide Cycle 
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(70). Cyclic schemes for the degradation and resynthesis 
of NAD+ have been proposed by Joshi and. Handler (130) and 
Sarma et al. (131). These schemes were postulated on the 
basis of data indicating that the nicotinyl moiety enters 
the pathway of NAD+biosynthesis de novo at the level of 
free nicotinic acid. Recently, it has been shown that the 
nicotinyl moiety enters the pathway as nicotinic acid 
mononucleotide which is formed from quinolinic acid and 
5-phosphoribosyl-l-pyrophosphate (112, 113). 
Considering these facts and the following information, 
Gholson (12) proposed a pyridine nucleotide cycle (Figure 
2). This cycle is based on the following evidence. 
Tryptophan serves as the de !.!QY.Q. precursor of quinolinic 
acid in mammals (61-64) and a number of organisms. In 
higher plants (79) and some bacterial species, Quinolinic 
acid is synthesized from glycerol and aspartate (80, 83, 
84) by an unknown series of reactions. Once at the levels 
of NaMN, biosynthesis appears to proceed via the so-called 
Priess-Handler pathway (70). NAD+ is cleaved by a number 
of enzymes, the most common being the glycohydrolase type 
which splits the NAD+ molecule to nicotinamide and 
AR.PPR. Nicotinamide released by this cleavage is con-
verted by deamidation to nicotinic acid (11). Other evi-
dence for the existence of this cycle is provided by the 
observation that when nicotinamide-14c-15N is injected 
into rats, the carboxyl group is almost undiluted, while 
there is considerable dilution of amide nitrogen in 
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hepatic: 1NAD+ ( 132). Data consistent with the operation of 
this cycle in plant have been reported by Waller et al. 
(133). 
Control of NAD+ Biosynthesis 
Most cells have the potential for synthesizing NAD+ 
by more than one metabolic pathway. Since the nicotina-
mide coenzyme concentration in these cells is usually 
remarkably constant, it is most probable that the opera-
tion of any given pathway will be regulated with respect 
to both existing nucleotide levels and the degree of oper-
ation of the other pathways. The most likely mechanism 
for the control of NAD+ levels will be summarized in the 
following paragraphs. 
It is well known that administration of small quanti-
ties of nicotinic acid to mice and rats brings about a 
rapid increase in the nicotinamide coenzyme levels in the 
liver. However, the administration of small quantities of 
nicotinamide does not bring about increased coenzyme syn.-
thesis. Hayaishi and coworkers have recently confirmed 
this phenomenon. This might indicate that NAD+ biosynthe-
sis from nicotinamide is under restraint of a physiologi-
cal control mechanism whereas that from nicotinic acid is 
not. Thus, the data of Hayaishi and coworkers could be 
interpreted as indicating that the liver cells of an adult 
mouse only make enough NAD+ to replace that lost in normal 
turnover. There are two enzymes which can initiate the 
net synthesis NAD+ from nicotinamide. They are nicot 
mide deamidase and nicotinamide ribonucleotide pyrophos-
phorylaseo Greengard and coworkers (11) have found an 
inhibitor in liver tissue which masks the nicotina:mi 
deamidse activity, and this inhibitor could be removed 
from deamidase by treatment with bovine serum al 
This indicated the enzyme, nicotinamide deamidase~ may be 
one control site for the biosynthesis of NAD+ i~ Y~.YQo 
In 1966, Dietrich et al. (125~ 126) showed the 
nicotinamide pyrophosphorylase activity in the extracts 
of a number of different cell types only after the removal 
of an inhibitory material by precipitation with pro 
sulfate o Thus~ the potential for control of the uti za"'" 
tion of nicotiamide is present. 
In 1966'! Dietrich and Muniz (13L~) reported that 
:n ic otin an'l ide ri bonucleotide pyrophosphorylase is subject 
to feedback control by NAD+. 'I1he levels of nicotinamid.e 
deamidase activity in liver do not seem to be affected by 
the N.AD+ concentration, but are greatly influenced by 
interplay of hypophyseal adrenal and thyroid hormones 
yiyQ ( 11, 123). ]'urthermore 'l the deamidase j_ s specific al-
ly inhibited by thyroxine i£ vitro (123). 
It has been known for a long time that the injection 
of large doses of nicotinamide into rats and mice resulted 
in large increase in the concentration of hepatic nicotin-
amide adenine dinucleotide (136)0 More recently~ Greengard 
and coworkers reported that hypophysectomy before 
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administration of nicotinamide results in an increase in 
both the degree and duration of the elevation of the con-
centration in liver (8)0 The same results were also re-
ported following the administration of nicotinic acid and 
tryptophan. Further experiments were carried out to iden-
tify the responsible hormones which might be involved in 
this effect by testing their ability to prevent the in-
crease of hepatic NAD+ concent;;tion in h;,vpophysectomized rats 
following the injection of nicotinamide. Greengard ~ al. 
(9) found that adrenalectomy, thyroidectomy~ and to a 
· .. · \\ . ,, 
'\:·. 
lesser extent/ gonadectomy were each effective in causing 
+ .. · •. · .. 
NAD level above that in normal rats. The high concentra-
+ 
tion of NAD in hypophysectomized rats could b~ greatly 
reduced by somatotropic hormone (9). Greengard et al.· (11) 
also reported that the activity of hepatic nicotinamide 
deamidase is responsible for the increase in hepatic NAD+ 
concentration in hypophysectomized rats following injec-
tion of large doses of nicotinamide. 
Another possible mechanism for regulation of NAD+ 
levels might be provided by NAD+ nucleotidase (NAD+ 
gly~ohydroiase). Kaplan (137) has postulated that this 
regulates NAD+ levels by destroying free NAD+ but n0t NAD+ 
bound to q.ehydrogenase. In this way, the level of NAD+ 
'\ffl'. 
and ·NAD*':r:equired dehydrogenase could be controlled. 
\r 
Biodegradation of Pyridine Nucleotide 
The degradation of nicotinamide adenine dinucleotide 
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in mammalian liver tissue was observed at a very earlier 
dateo However~ the characterization of the responsible 
enzymes has been carried out only recentlyo Several NAD+ 
degradative enzymes have been reportedo The enzymes which 
degrade NAD+ to NMN and AMP are NAD+ pyrophosphatase and 
NAD+ pyrophosphorylase (129 9 138)0 NAD~ pyrophosphatase 
catalyzes the cleavage of the pyrophosphate bond between 
the two ribose moieties producing nicotinamide mono-
nucleotide and adenylic acid from NAD+ and producing nico-
tinamide mononucleotide and 2'5'-diphosphoadenasine from 
NADP+o This enzyme has been observed in potatoes (129). 
ana kidney (138)0 NAD+ pyrophosphorylase catalyzes the 
reversible decomposition of NAD+ to NMN and ATP (73)0 
This enzyme has also been reported (70) to catalyze the 
reverse reaction yielding NAD+o The degradative enzyme 
which splits the bond between the ribose and nitrogen of 
the pyridine ring is NADase (NAD+ glycohydrolase)o This 
_. ·7 
enzyme also cleaves NMN to nicotinamide and ribose-5-
phosphateo This enzyme has been observed in erythrocytes 
(110 3 139) and Neuros_QQ£§! (140) o The function o.f NADase in 
the organism is still unclear (141) 9 however it can re-
lease nicotinamide by cleavage of NAD+ to permit lowering 
of NAD+ concentration in vivo when that is desirable~ so 
it may play some role in control of NAD+ levels in vivo 
(137)0 
In recent years~ Mandel et alo (147) discovered a 
nuclear enzyme which polymerizes the ADP-ribose moiety of 
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NAD+ with the release of nicotinamide: The polymer is 
formed of adenosine diphosphate ribose units linked be-
tween the c1 position of the terminal ribose and the c2 
position of the ribose attac~ed to adenine (142). The 
enzyme activity is exclusively localized.in c..llromatin (143.) 9 
and the polymer is linked to histone through a covalent 
bond (144). Bock and coworkers (145) have recently shown 
that the enzyme which polymerizes adenosine diphosphate-
ribose is probably identical to the previously reported 
nuclear NAD+ nucleosidase. 
CHAPTER III 
EXPERIMENTAL 
Chemicals 
Nicotinic acid-7-14c and nicotinamid.e-7-14c were pur-
chased from Calibiochem Inc., specific activity 12.4 me/ 
mmole. They were purified before use by paper chromatog-
raphy using n-butanol saturated.with 3% ammonia solution 
and n-butanol-acetic acid-water (4:1:2, v;v). Nonradio-
active nicotinic aoid and nicotinamide were purchased from 
Nutritional Biochemical Co., nicotinuric acid was pur-
chased from Calibiochem~, Inc., 6-hydroxynicotinic acid 
was purchased from Aldrich Chemical Company. 6-
hydroxynicotinamide was prepared by refluxing 11 grams of 
6-hydroxynicotinic acid with 10 ml of thionyl chloride in 
a water bath for one hour. The reaction mixture was 
slowly poured, with vigorous stirring, into 50 ml of ice-
cold concentrated ammonia. The product was collected by 
filtration and recrystalliz~d·twicefrom hot water, 
m.p. 285°0. Cel~ulose powder for preparation of thin 
layer. plates was purchased from Micro Chemical Specialties 
Co., Berkley, California. All other chemicals were of 
reagent grade and were obtained from. local supply houses. 
Dowex-1X8 formate, 200 to 400 mesh, was purchased 
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from the Bio Rad Company and was regenerated by washing 
successively with several volumes of 1 N hydrochloric 
acid, then with 4 N ammonium formate, and. then with 
deionized water until no more chloride ion could be 
detected coming off of the column by silver nitrate solu-
tion. Dowex-50-H+ form, 200 to 400 mesh, was purchased 
from Bio Rad, Company was regenerated by washing succes-
sively with several volumes of 2 N NaOH, then with 6 N HCl 
solution, and then with deionized water. 
Animals 
The normal rats used in this study were purchased 
from Holtzman Company, Madison, Wisconsin. All rats were 
maintained on a diet of Purina Laboratory Chow and fed 
ad libitum. Hypophysectomized rats were obtained from 
Hormone Assay Laboratory, Chicago, Illinois. The drinking 
water of hypophysectomized rats contained 5% glucose. 
Exp_eriments with hypophysectomized rats were carried out 
at 'i-e~st one week after surgery. Germ free rat experi-
ments were carried out in the Gnotobiotic Laboratory, 
Fitzsimons General Hospital, Denver, Colorado, by Nicholas 
Raica. The urines and wash solution were pooled, adjusted 
to pH 7.0 and stored frozen until lyophilized, and shipped 
to Oklahoma State University for analysis. 
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Methods 
Detection of Radioactivity 
The radioactivity on paper chromatograms was either 
determined with a Nuclear-Chicago 4n Actigraph III paper 
strip counter or the chromatograms were cut into 1 cm 
lengths and counted in a liquid scint'illation spectrometer. 
Radioactivity in liquid solutions was determined by 
pipeting 0.1 ml aliquots into 10 ml of scintillation fluid 
and counting with a Packard Tri-Carb Liquid Scintillation 
Spectrometer. The scintillation fluid was composed of 
600 ml toluene, 400 ml ethanol, 4.0 g of 2,5-
d.iphenyloxazole and 0.2 g of 1,4-bis [2-(5-phenyloxazolyl)] 
-benzene. 
Methods for Study of Nicotinic Acid and 
Nicotinamide Metabolism in Liver Tissue 
Administration of Nicotinic Acid-7-14c 
and Nicotin8.!l].ide~2~14c and Extraction 
of Radioactive Metabolites From the 
Liver 
The weights of the r,!3.ts used in these studies ranged 
from 100 to 150 grams. '11he method used for intraportal 
injection of nicotinic acid and nicotinamide was adapted 
from the method described by Hayaishi et al. (124). After 
laporot6myunder slight anesthesia, 0.05 ml of nicotinic 
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acid-7-14c or nicotinamide-7-14c solution containing 210 
mµmole of radioactive compound was injected via the portal 
vein during a period of 20 seconds. At various time inter-
vals after the termination of injection 9 namely, 20 
seconds, 2, 5, 10, 30, and 60 minutes, the liver was 
removed, weighed, and homogenized in 20 ml of 0.5% 
perchloric acid with mortor.and pestle at 0°C and centri-
fuged at 8000 rpm for 20 minutes. The precipitates 11vere 
washed twice with 10 ml of water, after combining the 
supernatants, the perchloric acid was neutralized with 
6 N KOH solution to pH 6.0, and precipitate of potassium 
perchlorate removed by centrifugation. The radioactivity 
in a 0.1 ml aliquot of the supernatant was determined by 
liquid scintillation counting. The total radioactivity 
recovered in the liver was calculated from this data. 
Analysi,s of the 1'1etaboli tes of Nictonic 
Acid-7-14c and.Nicotinamide-7~14c in 
the Liyer" Extract 
1. Paper chromatography: A 0.2 ml aliquot of 
liver extract supernatants solution was 
spotted on a Whatman No. 1 paper strip and 
descending paper chromatography was carried 
out 1 l'1 ammonium actate-ethanol (3:7 9 
pH5.0), pyridine-water (2:1 9 v/v) and 
isobutyric acid-ammonia-water (66:1.7:33~ 
pH 3.8). After developing and drying, the 
radioactivity on the chromatogram was 
located with a Nuclear-Chicago 4n 
Actigraph III paper strip counter. Alter-
natively, the paper strip was cut into 1 
cm pieces, placed in a counting vial with 
10 ml of scintillation solvent and counted 
by liquid scintillation spectrometry. 
2. Paper electrophoresis: A 0.2 ml aliquot 
of liver extracts was placed on a Whatman 
No. 1 paper strip 20 cm from one end and 
one end of the paper was dipped in buffer 
(pyridine:acetic acid:water (5.0:3.4:90, 
v/v) (146). The excess buffer was removed 
by blotting between two sheets of filter 
paper. This procedure was repeated to wet 
the paper at the other end. The paper 
strip was then placed in an electrophoresis 
tank in the proper position and 2000 volts 
was applied through a distance of about 
40 cm for 40 minutes. n-Hexane was used as 
coolant. The paper was removed from the 
tank, dried, and the radioactivity deter-
mined by paper strip counting. 
3. Ion exchange chromatography: A portion of 
the liver extract was placed on a column of 
Dowex-lx8 formate (2x20 cm, 65 ml). Elution 
was carried out with increasing 
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concentrations of formic acid (70) as shown 
in Figure 5. The flow rate was about 1 ml 
per minute. Fractions of 10 ml were col-
lected and 0.2 ml aliquots were counted in 
a liquid scintillation spectrophotometer. 
The radioactive fractionswere pooled and 
evaporated in .Y.§£Q to 1 ml. A 0.1 ml of 
this solution was spotted on Whatman No. 1 
paper strips with authentic samples and the 
strips were developed in different solvent 
systems. Quenching spots were detected 
under ultraviolet light, and the radioactiv-
ity on the paper chromatogram was determined 
by paper strip counting. 
Urin~~:_)'Ietab9li tes of Nicotinic Acid-z-14c 
and Nicotin8.!Jlide-1=14c in Normal and 
Hypop~ysectomized Rats 
I~trape£itoneal Injection of 14c Labeled 
Nicotinic Acid and Nicotinamide Into 
Normal and Hyp.2.£hysectomized Rats and 
Collection of the Urine 
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Holtzman strain rats weighing between 250 to 300 
grams were injected with 5 mg or 500 mg per kg of nico-
tinic acid or nicotinamide-7-14c dissolved in 0.9% saline. 
In all cases, the amount of radioactivity administered 
per rat was 5. 2 µ c. Three rats vrnre placed j_n a metabo"'" 
lism cage, arranged so that the urine was collected 
150 ml Erlenmyer flask which was immersed in a dry ice 
bath. At the end of each collection period, the cat;e v,ras 
washed with 50 ml of water. The feces from each period 
was also collected. Aliquots of. each urine fraction_ anc1 
washing were counted by liquid scintillation spectrometry, 
The total radioact~vity excreted in each period was calcu-
lated from this data. 
Ana.LY.sis of __ the Metabolite.s ____ of Nic.otinic 
Aciq __ ..§;gd l~iQ,.9tinamide in the Urine of 
Normal ___ ,and'" Hypq_:Qhy§_ectomized Rats 
1. Paper chromatography~ A 0.1 ml aliquot of 
each fraction was applied to Whatman No. 1 
paper strips and descending chromatography 
was carried out in n-butanol saturated with 
z~ · 1 t" :J/0 ammonia so u ion. Radioactive spots on 
the p2,per were located with Nuclear-Chicago 
paper strip counter, and compared with the 
Rf values of known compounds or with authen-
tic standards cbromatographed on the same 
paper, and located by ultraviolet quenching. 
2. Thin layer chromatography~ ,Glass plates of 
20x20 and 5x30 centimeters were spread with 
a 0.5 mm layer of MN 300G cellulose powder 
by using a commercial spreader apparatus. 
The coating material was prepared by blending 
15 grams of MN 300 G cellulose pov.Jder in 
110 ml of deionized distilled water for 5 
minutes. The chromatoplates were allowed 
to air dry for one hour, then activated in 
an oven at 70-80°C for one hour. The urine 
samples were applied to plate and developed 
in two different solvent systems.: n-butanol 
saturated with 3% ammonia solution and n-
butanol-acetic·acid-water (4:l:2j v/v). 
After developing and drying, the location of 
metabolites was determined with a paper 
strip counter and by quenching under ultra-
violet light. 
3. Dowex-50-H+ column chromatography: Ten ml 
of a water solution of urine solids was 
placed on a 2. 5x20 cm column of Dowex-50-:W. 
The column was eluted with water and 10 ml 
fractions were collected. Radioactivity was 
~·~ 
determined on 0.1 ml aliquots by liquid 
scintillation spectrometry and the absorbence 
at 290 mµ, was measured with a Beckman DU 
spectrophotometer. 
4. Dowex-lx8 formate column chromatography: The 
radioactive fractions obtained from Dowex-50-
H+ chromatography were reduced to dryness on 
a rotatory evaporator and dissolved in 5 ml 
Li-0 
of water. The samples were applied to 
2.5x20 cm Dowex-1-formate column. The 
column was eluted with water, fractions 
of 10 ml were collected, and the radio-
activity and absorbence were measured as 
above. 
5. Infrared spectrometry: Infrared spectra 
were determined with a Perkin-Elmer 457 
Grating Infrared Spectrophotometer in KBr 
pellets which were prepared by mixing 
about 1 µ g of unknown, which was isolated 
from urine by column chromatography and 
crystallized from hot water, and about 0.5 
mg of KBr powder and adding the mixture to 
a Perkin-Elmer IR Micro Sampling Accessory 
and compacted with an hydraulic presso 
6. Mass spectrometry: Mass spectra were meas-
ured using a prototype ( 146) of the LKB 9000 
combination gas chromatography-mass 
spectrometer instrument (Karolinska Institute, 
Stockholm, Sweden). , The sample in its solid 
state was introduced directly into the ion 
source through a direct inlet probe. The ion 
source temperature was 310°0, ionization cur-
rent was 65 milliamps, multiplier voltage 2.1 
kv, and acceleration voltage 3.5 kv. The 
mass spectra were computer plotted from 
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tabular intensity data with a CalComp using 
a Fortran 11-D program. The mass spectra 
were reported in terms of relative intensity, 
the most abundant ion being taken as 100%, 
and in term of sigma value. 
Measurement of Respiratory co2 
42 
During the collection of urine of rats injected with 
· t' 'd 7 14c · t· · 'd 7 14c th , nico 1nam1 e- - or nico 1n1c ac1 - - , e respira-
tory co2 was also collected by connecting the outlet of 
the metabolic cage to four co2 absorption tubes. The 
first three tubes contained 100 ml of ethanol amine in 
methylcellosolve (1:2,v/v), (148) and were used for col-
lecting the respiratory co 2 • The final tube contained 
50 ml of saturated barium hydroxide which was used as an 
indicator. The outlet of the final absorption trap was 
connected to a water asptrator. The co 2 trapping liquids 
were combined and 3 ml of this liquid were added to 15 ml 
of methylcellosolve-toluene (1:2,v/v) which contained 
5.5 grams of PPO per liter, for measuring the radioactvity 
in a liquid scintillation counter. 
C H.AJ?TER IV 
RESULTS AND DISCUSSION 
Results 
Paper_Chromatographic Separation of 
Nic9_"t_iniQ_Acid and Nicotinamide Metaboli~~s 
Paper chromatography has been widely applied for the 
separation of the metabolites of nicotinic acid and its 
amide in the urine or in tissue extracts o 1rhe most common 
solvents used for the separation of urinary metabolites 
are n-butanol saturated with 3% ammonia solution (118~ 
11.~9) or n-butanol saturated with water ( 110). These 
solvents give a good separation of urinary metabolites, 
except for nicotinuric acid and N1-methylnicotinamid.e. 
Hov11ever, these tvv0 compounds can be easily separated. by 
adding l ml of glacial acetic acid to 60 ml of n-butanol 
saturated with water. In this solvent system~ the Rf o.f 
N1-methylnicotinamide is essentially unchanged. (Rf 0.08)~ 
whereas the Rf of nicotinuric acid increases to 0.5 (1 ). 
Hence, radioactive material which chromatographed with Rf 
0.04 in the basic solution was eluted with water and ap-
plied to a new strip of filter paper for chromatography 
in the acidic solvent. 
43 
The solvent systems 9 l M ammonium acetate-ethanol 
(3:7, pH 5.0), isobutyric acid-ammonia-water (66:lo7:33, 
pH 306) and pyridine-water are the most common solvents 
44 
used for separating of the pyridine nucleotides') nicotinic 
acid mononucleotide 9 nicotinamide mononucleotide, 
desamido-NAD and nicotinamide adenine dinucleotide 9 but 
the non-nucleotides are all located at Rf 0.65-0085 in 
these solvents. These non-nucleotides were further sepa-
rated by eluting from the paper chromatograms which were 
developed 1 M ammonium acetate-ethanol at Rf 0065-0.85 9 
and rechromatographing in n-butanol saturated with 3% 
ammonia solution. The Rf values of all nicotinic acid 
-metabolites are shown in Table I. 
Thin Layer Chromatography an ... d 
Paper Electrophoreili 
l"1N 300 G cellulose powder thin layer plates were used 
for the separation of nicotinamide urinary metabolites. 
This system has the advantage of separating N1-
methylnicotinamide, 6-hydroxynicotinic acid and nicotinuric 
acid with n-butanol saturated with 3% ammonia solvent. 
Indeed, the newly discovered metabolite~ 6-
bydroxynicotinic acid always has the same Rf as nicto-
tinuric acid in both acidic and basic solvent systems dur-
ing paper chromatography; however 9 nicotinuric acid can be 
separated from N1-methylnicotinamide and 6-hydroxynicotinic 
acid. The later two compounds can be further separated by 
r_r,:iBLi~ I 
DEbCEJ\rDI:NG :Pi\TEH CH:d.OM/1.'J:OC·B.JJ?HY O.b' 1rrr.,: I'lET..:~BOLITES 
Oii' NICocrnnc ACID AND Ji:ICUJ:INAViIDE 
Mobili ties 1 
( cm/hr • kv. ) 
If:) 
Rf Value 
1-'aper Chromatography 'r.1.c. Electrophoresis 
dolvent System Buffer 
I II III IV III A B 
Nl-methylnicotinamide 0.69 0.81 0.03 0.64 o.os -8.0 -9.0 
Nicotinuric acid 0.66 o.67 0.03 o.64 0.77 5.3 6.2 
Nicotinic acid 0.67 0.71 0.15 0 .75 0.28 5.7 6.5 
Nicotinamide-N-oxide 0.10 0.76 0.25 0.62 0.32 2.0 o.o 
2-1-'yridone a.so 0.85 0.41 0.72 0,40 o.o o.o 
4-Pyridone 0.71 0.85 0,49 0 .72 0,58 o.o o.o 
Nicotinamide 0 .75 0,82 0 .68 0 .78 0.72 0,0 -0.5 
6-Hydroxynicotinic acid 0 .75 a.so 0.03 0.75 0.15 5.5 6.2 
6-Hydroxynicotinamide 0.78 0.82 0.24 0 .75 0.31 o.o o.o 
Na MN 0.21 0.35 o.oo 0.30 o.oo 5.5 
NMN 0.25 0.48 o.oo 0.30 o.oo 1.2 
Deaamido-NAD 0.12 0.30 o.oo 0.15 o.oo 5.2 
N.AD 0.16 0.43 o.os J,08 o.oo 2.3 
Solvent: 
I. 1 M ammonium acetate-ethanol (3:7, v/v) 
II. isobutyric acid-ammonia-water (66:1.7:33, v/v, pH3 .B) 
III. n-butanol sa.turated with 3Yo ammonia solution 
. IV• n-butanol-acetic acid-water ( 4 :ll.;2 ,·. viv) 
Buffer 
A. 0.05 M sodium borate 
B. 
1. pyridine-a~e~ia.acid-w~ter (5.0i3.4:~0t"v/vn dH +and-mar in icate m1~rat1on owar n0 a o e &n~)cathode 
reapectiveJ.y. 
paper electrophoresis in 0.05 l'1 sodium borate buffer. 
Paper electrophoresis was used for the separation of 
pyridine nucleotides where the buffer was pyridine-acetic 
acid-water (5.0 3.4~90,v/v, pH 5.0) (146). The Rf values 
from thin layer chromatography and the mobility on high 
voltage paper electrophoresis of the nicotinic acid and 
nicotinamide metabolites are shown in Table I. 
Isolation and I9:er1tif_ication of 1'1etaboli t~.§. 
Form~d i~ the _Live:£ of Nicotinic Acid-7-140 
I]ljected Rats 
Samplesof 20 ml of liver extract were applied to a 
Dowex-1-formate form (2.5x20 cm) column, the column was 
eluted with water followed by increasing concentrations of' 
formic acid (70). The results are shown in :Figure 3. 
Five radioactive peaks were isolated. Each peak was 
J)Ooled together, concentrated under reduced pressure, and 
identified by paper chromatography with authentic samples 
in different solvent systems. These radioactive peaks are 
in the order of elution) N1-methylnicotinamide, nicotina--
mide, nicotinic acid plus NAD+, nicotinic acid mononucleo-
tide and desamido-NAD. 
~etabolism of ~icotinic_Acid-7-:4c 
and Nicotinamide-7-14c ~n the Liver 
of Hypo£hysectomized and Normal Rats 
Each rat in these experiments was injected with 
Figure 3. Chromatographic Separation of the Metabol es 
of Nicotinic Acid in Liver Extracts on a 
Dowex-lx8 Formate Column 
20 ml of liver extract from nicotinic acid 
injected rats was applied to 2.5x20 cm Dowex-lx8 
formate column. The column was eluted vJi th 
water and then increasing concentrations of 
formic acid as shown. The metabolj_tes were 
identified by descending paper chromatography in 
several different solvent systems with authentic 
markers. 
peak 1 N1 -methylnicotinamide 
peak 2 nicotinamide 
peak 3 nicotinic acid and NAD+ 
peak 4 nicotihic acid mo:honucleotide 
peak 5 desamido-NAD 
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2.0 µc (210 mµ moles) or 1.0 µc (75 mµ moles) of nic c 
ll~ . ·1 /i 
acid-7- C or 2.0 µc (210 mµ moles) of nicotinamide-7-~~c 
into the portal vein. The liver of each rat was homage-
nized and extracted according to the method of Hayaish~ 
(124). As shown in Figure 4, the total radioacti vi t;y· re-
maining in liver was almost constant from 10 to 60 minutes 
after injection. When comparing the difference between 
normal and hypophysectomized rats, the total radioactivity 
recovered from hypophysectomized rats vms slightly higher 
than that from normal ratso The radioactivity recovered 
in the liver of nicotinic acid injected rats war3 also 
higher than that in nicotinamide injected rats. 
The distribution of hepatic metabolites following 
· · · · · d 7 14c · · t · t 1 · ., · t 1 t 1 n1co~1n1c ac1 - - 1nJec ion grea y var1en w1-n 1e 
dosage injected, as shown in Figures 5 and 6. A srn.all 
amount of NaMN and desamido-NAD+ was ob served within the 
st few minutes following injection of both 75 mµ. mole 
and 210 rn.µ mole per rat of nicotinic acid, while the 
radioactivity in NAD+ increased with time, reaching a max-
imum about 10 minutes after injection of 75 mµ moles of 
cotinic acid. However, when 210 mµ moles of nicotinic 
acid were administered, the radioactivity in NAD+ reached 
a maximum in about 5 minutes and then decreased to two-
thirds of the maximum value after 60 minutes. There was 
no major difference between normal and hypophysectomized 
rats. The non-nucleotide also appeared within 2 minutes 
t 
after injection of nicotinic acid. Nicotinamide 
J?igure 4. Total Radioactivity Recovered in the Liver 
of Hypophysectomized and Normal Rats 
After Portal Vein Injection of 14c 
Labeled Nicotinic Acid and Nicotinamicle 
Experimental procedures are described in 
Chapter III. Each value represents the ave 
of three experiments. 
-b,. ... -6- , nicotinic acid (210 mp, moles) 
normal rats 
~-A--~ nicotinic acid (210 mµ moles) in 
hypophysectomized rats 
nicotinamide (210 mp, moles) in 
normal rats 
nicotinamide (210 mµ moles) in 
hypophysectomized rats 
--0,---f!-, - 1 nicotinic acid (75 mp, moles) in 
normal rats 
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Figure 5. The Metabolism of Nicotinic Acid in the 
Liver of Hypophysectomized Rats After 
Intraportal Injection of Nicotinic 
Acid-7-140 (210 mµ moles) 
Compounds were separated by descending 
paper chromatography in the 1 M ammonium 
acetate-ethanol solvent system. The non-
nucleotide metabolites were separated by 
rechromatography of the sample, which was 
eluted from the above chromatogram between the 
range of Rf 0.65-0.85 in the n-butanol satu-
rated with 3% ammonia solvent system. The 
radioactivity.of each peak was measured by 
cutting the paper chromatogram into 1 cm 
pieces, and counting by! liquid scintillation 
spectrometryo 
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Figure 6.. The Metabolism of Nicotinic Acid in the 
Liver of Normal Rats After Int1~portal Injection of Nicotinic Acid-7- C 
(210 and 75 mµ moles) 
Experimental procedure same as Figure 5. 
210 mµ mole dose: 
0
--·.IA---.l:r -··, desamido-NAD; 
---m • , nicotinamide; -~ , nicotinic 
acid; 
-, 
... ...;..m,.~-.~J- -- , N1-methylnicotinamide; 
75 mµ mole dose: 
-o---o-.' NAD; ---o~--o-·-·, NaMN, 
--· -1:::s---br-..;. , desamido-NAD; 
--~-o--, nicotinamide; ---A--b--, nicotinic 
acid 
--0--<J..-..:.., N1-methylnicotinamide 
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MINUTES AFTER NICOTINIC ACID INJECTION 
constitutes about 80% of these metabolites. After 
istration of a small dose of nicotinic acid~ only a 
small amount of nicotinamide (2-5%) was formed within 
one hour experimental period. However, when the hi 
doses of nicotinic acid were administered, the formation 
of nicotinamide was rapid and constituted up to 15% 
the dose, increasing with time as shown in Figures 5 
6. 
The fate of radioactivity in the liver of nicotinam:Lde 
7 14c . . t d rats . 1 ' ]", . 7 I t ,__ ;, ~- - inJec e is s 1own in · igure . n con .ras1; ·cc 
the results obtained with nicotinic acid, only a small, 
but definite, incorporation of nicotinamide into NAD+ .)-
v\ras observed immediately after the injection and no in--
crease of NAD+-14c occurred during the entire e:x:perimental 
period in both normal and hypophysectomized rats. There 
war, no detectable nicotinamide nucleotide intermediates, 
Nru'VJ:N·; NMN, or desamido-NAD in the liver within 60 minutes 
F't . . t. f . t. . d 7 14c N1 th 1 . t. a~ er inJec ion o· nico 1nam1 e- - • -me y nico ina-
mide and nicotinamide-N-oxide were synthesized within 20 
freconds after injection. N1-methylnicotinamide was a 
major metabolite in the liver a short time after the :in--
jection of nicotinamide. The formation of N1-
methylnicotinamide reached a maximum in two minutes after 
injection of nicotinamide in normal rats and constituted 
about 70% of the total radioactivity in liver, then 
rapidly disappeared from liver. In hypophysectomized 
rats, the formation of N1-methylnicotinamide reached a 
57 
maximum in five minutes. The rate of excretion of 
N1-methylnicotinamide from liver was slower than in 
normal rats, as shown in Figure 7. There was also present 
1-2% of 2- and 4-pyridone in the metabolites in hypo-
physectomized rats, which were not found in normal rats. 
The Metabolites of Nicotinic Acid-7-140 
and Nicotinamide-2-140 in the Urine of 
Normal and Hypoph,ysectomized Rats 
It has been reported by Greengard and coworkers (8) 
that hypophysectomized rats have a higher concentration of 
hepatic NAD than normal rats following the intraperitoneal 
injection of nicotinamide. In order to determine the 
effect of hypophysectomy on nicotinamide metabolism in 
t · t· ·d 7 14c · t' · ·d 7 14c t · 'h ra s, n1co 1nam1 e- - · or n1co 1n1c ac1 - - a e1~ er 
a 5 mg/kg or 500 mg/kg level was intraperitoneally in-
jected into both normal and hypophysectomized rats and 
both the quantity and the distribution of metabolites in 
the urine was compared. The results of these experiments 
are shown in Figure 8. Little difference was observed 
between normal and hypophysectomized rats when injected 
with 5 mg/kg of nicotinic acid-7-140. However, with large 
doses of nicotinic acid-7-14c (500 mg/kg) normal rats 
excreted 20-30% more radioactivity in the 0-3 and 3-6 
hours time periods. 
The total radioactivity excreted in the urine after 
injection, of nicotinamide-7-140 is shown in Figure 9. 
'l'i CJ" 8 7 
.I. ·-c,Ur • The Radioactivity Distribution of Nicotinamide 
Metabolites in the Liver of Normal and 
Hypophysectomized Rats After Intraportal 
Injection of 210 mµ Moles Nicotinamide-14c 
Experimental procedure same as Figure 5. 
Hypophysectomized rats: 
··-o-··· o-- NAD :1 -f::s-. . - .. -···b._·· -·, · nicotinamide; 
--·--~ ., N1 -methylnicotinamide; 
.. -o- ~ -~ ...... , nicotinamide-N-oxide 
- --t::;:. -- -tr ... , 2 and 4- pyridone; 
Normal rats: 
·····f~)-·-{'J)--· ·; NAD; ----Vt.~ N1-metl)ylnicotinamide; 
t: 
·--,1\--&h.--- , nicotinamide; 
... -~,:;-,. .. ~:-· nicotinamide-N-oxide 
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Figure 8. The Excretion of Total Radioactivity the 
Urine of Normal and Hypophysectomized. 
Rats Following the Injection of 500 mg/kg 
or 5 mg/kg Nicotinic Acid-7-14c 
The radioactivity in the urine is 
expressed as a percentage of the administered 
dose. Each value is the average of t1t,TO ex:p,ar1·~ 
m.ents, each experiment contained pooled 
of three rats. 
In hypophy9ectomized rats~ 
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Figure 9. The Excretion of Radioactivity in the Urine 
of Normal and Hypophysectomized Rats 
Following the In,jection of 500 mg or 5 mg 
of Nicotinamide-7140 
The radioactivity in urine is expressed 
as a percentage of the administered dose. Each 
value is the average of two experiments, each 
experiment contained pooled urine of three ratso 
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HOURS AFTER NICOTINAMIDE INJECTION 
After the small dose (5 mg/kg), normal rats excreted 37.0% 
of the administered vitamin, which was three times greater 
than that excreted by hypophysectomized rats within the 
first three hour period after injection. Following the 
loading dose (500 mg/kg), normal rats excreted 70.4% of 
the radioactivity in the urine, however~ hypophysectomized 
rats only excreted 42.8% of the radioactivity in the urine 
within 24 hours after injection of the vitamin. 
The distribution of radioactivity among the metabo-
lites in the urine of normal and hypophysectomized rats 
within 24 hours after injection of 5 mg or 500 mg per kg 
I, 
nictonamide is shown in Table II. After small doses, the 
normal rats excreted more N1-methylnicotinamid·e than did 
the hypophysectomized rats, while the hypophysectomized 
rats excreted more N1-methyl-2-pyridone-5-carboxamide and 
N1-methyl-4-pyridone-3-carboxamide than the normal rats 
within 24 hours after injection. In loading experiments~ 
the normal rats excreted 11.7% of N1-methylnicotinamide in 
the urine within 24 hours after injection. However, hypo-
physectomized rats only excreted 2.5% of N1-
methylnicotinamide. Normal rats also excreted more 
nicotinamide-N-oxide and unchanged nicotinamide than did 
the hypophysectomized animals within 24 hours after injec-
tion. In both normal and hypophysectomized rats, the 
excretion of nicotinic acid and nicotinuric acid was 
-greatly increased by injection of loading dose (500 mg/kg) 
of nicotinamide. 
TABLE II 
RADIOACTIVITY DISTRIBUTION AMONG URINARY METABOLITES OF NORMAL AND HYPOPHYSECTOMIZED RATS 
FOLLOWING THE INJECTION OF 500 mg/kg OR 5 mg/kg OF NICOTINAMIDE-7-14c 
Hypophysectomized Rats I Normal Rats 
Hours After InJection 
0-~ :2-6 6-9 9-24 0=24 I 0-3 !-6 6-9 9-24 
Metabolite 
I 
Per Cent of InJected Dose 
I 
Small dose (5 mg/kg) 
Nl-methylnicotinamide I 7.2 2.8 6.9 2o2 19ol 24.1 1206 7.3 3ol 
Nicotinuric acid 0.1 o.6 o.4 0.3 1.4 Oo3 0.3 0.3 o.6 
6-Hydroxynicotinic acid 
- - - -
o.4 
- - - -
Nicotinic acid o.6 1.5 0.9 0.5 3o5 1.1 o.4 0.2 0.1 
Nicotinamide-N-oxide 0.2 0.7 1.0 Oo6 2.5 0.3 0.3 o.4 o.4 
2 and 4-Pyridone* I L7 2.3 7.3 3.7 15.0 6.1 1.6 1.4 o.8 6-Hydroxynicotinamide = 
- - -
0.5 = - - -
Nicotinamide i o.8 5.8 o.6 2.9 0.9 1.2 5.1 1.0 0.1 
Total 12.7 8.7 17.4 8.5 47.3 37.0 15.8 10.6 5.1 
High dose (500 mg/kg) 
Nl-methylnicotinamide 
I 
1.2 o.6 0.5 0.3 2o5 I L8 2.0 2.1 5.8 6-Hydroxynicotinic acid 
- -
- -
o.6 i = = = -
Nicotinuric acid 
-
;.O 1.4 1.7 6.1 L8 2.5 0.3 3.4 
Nicotinic acid 0.2 1.0 L8 6.1 9.1 1.5 1.5 L6 L5 
Nicotinamide-N-oxide 0.1 0.9 1.0 o.6 2.6 1.1 1.1 1.8 2.8 
2 and 4-Pyridone* 
-
0.3 o.4 o.6 1.3 0 7. Q.,,, o.4 1.2 0.5 
6-Hydroxynicotinamide 
- - - -
0.7 = 
- - -
Nicotinamide ;.8 4.6 3.4 8.1 19.9 9.8 8.2 ?.l 9.1 
Total 5.3 10.8 8.7 18.0 42.8 16.4 15.9 14.3 23.4 
-
*2-pyridone~ N-methyl-2=pyridone-5-carboxamide 
4=pyr:idone~ Nl=methyl-4-pyridone-3-carboxamide. 
0-24 
47ol 
1.5 
0.3 
1.8 
1.4 
9.9 
o.6 
6.8 
68.5 
11.7 
o.4 
8.o 
6.1 
6.8 
2.4 
o.8 
34.2 
70.4 
G'l 
\Jl 
Table III shows the radioactivity distribution 
nicotinic acid metabolites after the intraperitoneal 
administration of 5 mg or 500 mg of nicotinic acid--
into normal and hypophysectomized ratso The rate o.f 
excretion of nicotinic acid in hypophysectomized rats was 
reduced from that of normal rats. As in the nicotinamide 
injected rats, normal rats excreted more N1-
methylnicotinamide in the urine than did the hypo~ 
physectomized rats after small doses of nictonic aci 
7_14c. 
During these studies of the urinary metab tes 
nicotinic acid and nicotinamide ~ small amounts of 1.u1,--
known compounds which have not previously been rep ect EtS 
mammalian metabolites were discovered. The isolation and .. 
::.dentification of these two compounds will be detailed 
the following chapter. 
Discussion 
It is well known that the biosynthesis of nicot 
mide adenine dinucleotide from nicotinic acid. occ1.1r::: a 
nicotinic-acid mononucleotide and desamido-NAD"~ ( ?O) . 
in ~iY.Q. experiments reported here which followed the fate 
of nicotinic acid-7-14c (75 and 210 mµ moles) injected 
into the portal vein provide supporting evidence for the 
functioning of this pathway. A rapid conversion of nico~-
tinic acid to nicotinic acid mononucleotide, desamido-
NAD+ and NAD+ was observed in the liver within one minute 
TABLE III 
RADIOACTIVITY DISTRIBUTION AMONG URINARY METABOLITES OF NORMAL AND HYPOPHYSECTOMIZED RA4s FOLLOWING 
THE INTRAPEDITIONEAL INJECTION OF 5 mg/kg OR 500 mg/kg OF NICOTINIC ACID-7-1 C 
HiEoEhisectomized Rats I Normal Rats 
0- -6 6-
Hours After InJect1on 
9-24 0-24 0- -:z , 
-6 6- 9-24 0.24 
Metabolite Per Cent of InJected Dose 
Small dose (5 mg/kg) 
Nl-methylnicotinamide 1.6 2.1 0.5 ··1o6 5.7 .}~2 L2 3.1 4.9 14.8 
Nicotinuric acid 13.7 6.6 0.7 0.5 21.5 18.0 6.1 1.0 1.5 26.6 
6-Hydroxynicotinic acid 
- - - - - - - - -
1.0 
Nicotinic acid 4.5 o.6 0.1 0.2 5.4 4.6 1.3 - o.4 6.3 
Nicotinamide-N-oxide 
-
0.9 0.2 0.7 1.8 0.2 0.1 0.2 0.1 0.5 
2 and 4-pyridone* 
-
o.6 0.2 1.8 2.6 0.1 0.1 0.2 0.1 0.5 
N1cotinam1de 
j 14~8 
o.8 0.1 0.2 1.1 
-
0.5 0.3 0.2 LO 
Total 12.6 1.8 5.8 41.1 26.1 9.6 6.9 7.8 50.4 
:;fgh dose (500 mg/kg) I 0.2 0.3 0.2 1.2 1.9 0.2 0.3 0.3 2.0 2.8 N -methylnicotinamide Nicotinuric acid l 0.5 1.6 1.6 2.5 6.2 4.8 1L7 2.3 1.1 19.5 
6-Hydroxynicot1n1c acid I - - - - 0.7 - - - = o.8 
Nicotinic acid i 11.9 14.1 9.3 13.2 48.2 34.9 20.1 5.6 0.7 60.9 
Nicotinamide-N-oxide 
-
0.1 0.2 0.7 1.0 0.2 0.3 0.3 1.0 1.8 
2 and 4-Pyridone* j 0.1 0.5 o.4 o.6 1.6 - - 0.1 0.1 0.2 
6-Hydroxynicotinamide I - - - = = ! -:zo:6 - - - -Nicotinamide I 0.1 0.1 0.2 0.1 0.5 0.7 0.1 0.3 1.7 
Total 112.9 16.2 12.0 18.2 59.3 I .,,9.9 33.2 9.0 5.6 87.7 
*2-pyridone, Nl-methyl-2-pyridone-5-carboxamide 
4-pyridone~ Nl-methyl-4=pyridone-3-carboxamide 
Each value is the average of two experiments which contained three rats in each experiment °' --...J 
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after injection. The radioactivity in NAD+ reached a 
maximum in ten minutes after injection, whj_le radioactive 
nicotinic acid mononucleotide and desamido-NAD+ were only 
observed within a short time after injection. When the 
same experiment was repeated with nicotinamide-7-14c, the 
incorporation of radioactivity into NAD+ was quite small 
when compared to that of nicotin'ic acid. No nicotinic 
acid mononucleotide, desamido-NAD or nicotinamide mono-
nucleotide was detected during the experimental period. 
~ 
All these data are in agreement with the previous report 
by Hayaishi and his coworkers (124). 
These results suggest that the control mechanisms 
which regulate the biosynthesis of NAD+ are not present 
between nicotinic acid and NAD+ while the biosynthesis of 
NAD+ from nico~inamide is under the restraint of a physio-
logical control mechanism. There are two·reported reac-
tions .which initiate NAD+ bios,ynthesis from nicotinamide~ 
namely nicotinamide deamidase and nicotinamide mono-
nucleotide pyrophosphorylase. These two enzyme activities 
are inhibited by endogenous substances which have been 
reported by Greengard (11) and Dietrich (125, 126), 
respectively. The results obtained from intraportal 
injection of nicotinamide were.quite different from those 
published by Hayaishi's group (35),who reported that nico-
tinamide injected into the portal vein was rapidly 
excreted from the liver and stored in gastrointestinal 
tract, where it was deamidated to nicotinic acid and 
reabsorbed into liver cells for NAD·biosynthesis. 
ever, the present results obtained by intraportal in.~jec-.. 
tion of nicotinamide show that nicotinamide is rapidly 
methylated to N1-metbylnicotinamide and excreted from. the 
liver. About 80% of the radioactivity recovered in the 
liver was present in N1-metbylnicotinamide within 2-5 
minutes after injection of nicotinamide-7-14c. Similar 
results were also reported from rat liver perfusion experi-
ments by Henderson and coworker (149). These findings 
suggest that methylation of nicotinamide in the liver ma;y 
play a role in the control of nicotinamide concentration. 
Whether N1-methylnicotinamide can be further utilized 
NAD+synthesis or is only excreted in the urine is not yet 
known. 
Another interesting result was the rapid conversion 
of nicotinic acid into nicotinamide and its derivatives. 
It is known (7) that nicotinamide can onlyf:pe formed in 
,-,.,;..-.' 
mammalian liver from the degradation of NAD+or NMN. Thus~ 
the nicotinamide formed in these experim~ni/:S had to be 
~ ,,.... .,-.:·:~~ 
considered as a degradation product of NAD~. There are 
several enzymes which are involved in the degradation of 
NAD+. These are NAD+-pyrophosphorylase 1 NAD+-phosphatase~ 
NADT-glycohydrolase and ARPPR polymerase. However, the 
first two enzymes may be tentatively excluded because no 
Nl'1N can be detected in the liver extracts:. The enzymes 
:,: 
which probably form nicotinamide from NAD+are NAD-
glycohydrolase or the nuclear enzyme which polymerizes the 
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ARPPR moiety of NAD+ with release of nicotinamide. How-
ever, Bock and coworkers (145) have recently reported that 
the nuclear NAD+ nucleotidase 'is probably identical with 
the enzyme which polymerize the adenosine diphosphate 
ribose moiety of NAD+:·into an acid insoluble polymer. The 
formation of nicotinamide · i_ncreased with increasing dosage 
of nicotinic acid probably due to the increased activity 
in the presence of the abnormally high concentration of 
NAD+ which is formed from the nicotinic acid in the 
hepatic tissue within a short time after injection. In 
order to reduce the NAD+ concentration in the liver to 
normal levels, the NADase could degrade the excess NAD+ 
in the liver, under normal conditions. Possible mecha-
nisms for increased NADase activity could be either in-
creased NADase synthesis or the NADase activity could be 
stimulated by high concentrations of.NAD,i.. 
In the urinary studies comparing hypophysectomized 
and normal rats after injection of 5 mg or 500 mg per kg 
of nicotinamide or nicotinic acid, the rate of excretion 
of vitamin in hypophysectomized rats was slower than that 
in normal rats. Further, the rate of excretion of 
N1:'...metbylnicotinamide and nicotinuric acid in the urine 
of hypophysectomized rats was also slower than in normal 
rats. The percentage of nicotinic acid excreted in the 
urine of hypophysectomized rats within 24_hours following 
the injection of nicotinamide was greater than that in 
normal rats. This resul tr,, agrees with the previous report 
that hypophysectomiz.ed rats have a greater n:Lcot 
deamidase activity in the liver than do normal rats (156). 
Nicotinuric acid and N1-methylnicotj_namide are the 
metabolic end products of administered nicotinamide and. 
nicotinic acid. N1-methylnicotinamide can bc-3 further 
oxidized to N1-methyl-2-pyridone-5-carboxamide and 
1 
N~-methyl-4-pyridone-3-carboxamide in vivo and these 
compounds also excreted in the urine. ~Che small amount 
and slow rate of the excretioh of nicotinuric acid and 
N1-methylnicotinamide in hypophysectomized rats followed 
the injection of nicotinamide and nicotinic acid indicates 
that the hypophysectomized rats have a reduced capacity 
to dispose of the administered vitamin. The forrnation of 
nicotinamide derivatives in the nicotinic acid injection 
experiments presumably results from nicotinamide formed by 
degradation of NAD+. In normal rats, the nicotinamide 
formed from degradation of NAD+ was largely excreted in 
the urine as N1-methylnicotinamide (5.7% within 24 hours 
after injection of nicotinic acid). However, hypo-
physectomized rats only excreted one-half the amount of 
N1-methylnicotinamide which was excreted by normal rats. 
This provides a possible explanation for the increased 
hepatic NAD+ concentration in hypophysectomized rats fo 
lowing the injection of nicotinic acid. 
In conclusion, the effect of hypophysectomy on nico-
tinamide deamidase, the slow rate of excretion of the 
injected vitamin and the slow rate of methylation of 
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nicotinamide in hypophysectomized rats provide a possible 
explanation for the greatly increased magnitude and dura-
tion of hepatic NAD+ concentration following the injection 
of nicotinamide or nicotinic acido 
Another interesting result in both normal and hypo-
physectomized rats was the greatly increased excretion of' 
nicotinic acid and nicotinuric acid following the intra-
periotoneal injection of a large dose of nicotinamideo It 
is known that the synthesis of NAD+ in hepatic tissues is 
initiated by conversion of nicotinamide to nicotinic acid 
by nicotinamide deamidase. This hepatic enzyme has been 
found to have high K111 value (4 x 10= 2 to 2.5 x 10- 1 1'1) (11~ 
119) and its activity in crude extracts is masked by an 
endogenous inhibit;oro The injection of a large dose of 
nicotinamide may overcome its high Km value of nicotiamide 
deamidase in liver or cause the removal of the endogenous 
inhibitor in YiY.Q.. 
CHAPTER V 
ISOLATION AND IDENTIJ!"'ICATION OF TWO NEW 
URINARY NICOTINAMIDE METABOLITES 
During the course of quantitative studies on the 
metabolism of nicotinic acid in hypophysectomized rats 
following the injection of 5 mg per kg of nicotinic acid·-· 
7-14c, a previously unreported urinary metabolite of 
nicotinic acid was observed 0 This compound had chroma,,~ 
tog;raphic behavior similar to nicotinuric acid in n,-
saturated with 3% ammonia solution and n-butano acet 
Q0~? r~·l·2 V/V) u,-...,...LU. \ r" o CJ . 0 However, it could be separated from 
nicotinuric acid on cellulose powder thin layer plates 
us n--butanol saturated with 3% ammonia solution as a 
d.eveloping sol vent. The unknown was tentatively identi-
f1_0d as 6-hydroxynicotinic acid by comparison of its 
tion during electrophoresis and column and paper 
ch:romatography with that of authentic 6-hydrox;y-nicot c 
acid_" 
Isolation of Unknown Metabolite 
In order to positively identify this unknovm compound~ 
three 200 to 300 gram male rats were intraperitoneally 
injected with 500 mg/kg nicotinic acid-7-14c (50 mg/ml). 
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The urine was collected for 24 hours after injection. The 
collected urines were pooled together and evaporated to 
dryness under reduced pressure at 50°C. The residue was 
dissolved in 10 ml of water and applied to a 2 o 5 x 30 cm 
Dowex-50-H+ column which was eluted with water. Figure 10 
shows the resulting elution patterno The first radioac-
1 ti ve peak contained the unknown and N -methyl-2-
pyridone-5-carboxamide o This peak was pooled and evapo-
rated to l ml under reduced pressure. This solution was 
then applied 4o Whatman No. 1 paper and developed by 
descending chromatography using n-butanol saturated with 
3% ammonia as a developing solvent. The unknown was 
eluted from paper with water and rechromatographed in 
n-butanol-acetic acid-water. The radioactive peak on the 
... 
ch.r~pmatogram was eluted with water and further purified 
by recrystallizing from hot watero 
Identification of Unknown Compound 
This new metabolite crystallized as white needles and 
had a melting point of 304°C with decomposition. The mass 
. spectrum of the unknown compound (Figure 11 9 upper 
spectrum) was almost identical with that 6-hydroxynicotinic 
acid (lower spectrum). Both compounds have a molecular 
ion of m/e 139 and fragment ions of m/e 122 9 111 9 94 9 66 9 
41, 39, and 28. The postulated route of formation of 
these ions is.given in Fig~re 12. The molecular ion 9 
m/e 139~ loses an OH to form ion m/e 122 9 further loss of 
Figure 10. Isolation of Unknown Compound From the 
Urine of Nicotinic Acid Injected Rats 
by Dowex=50-W Column Chromatography 
Ten ml of a water solution of urine was 
placed on a 2. 5 x 20 cm column of·· Dowex-50-H+. 
The column was eluted with water and 10 ml 
fractions were collected. Radioactivity was 
determined on 0.1 ml aliquots by liquid 
scintillation counting and the absorbance at 
290 mµ measured with a Beckman DU Spectropho-
tometer. The radioactive peak contained a 
mixture of N ° =methyl-2-pyridone=5=carboxamid.e 
and the unknown compound. 
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Ii11gure 11. :Mass Spectra bf Authentic 6-Hydroxynicotinic 
Acid and the Compound Isolated From the 
Urine of Nicotinic Acid Injected Rats 
Mass spectra were determined using the proto-
type (146) of the LKB-9000 gas chromatograph-mass 
spectrometer using the direct inlet probe. The ion 
source temperature was 70 eV, and acceleration 
voltage was 3.5 volts. The mass spectra were 
computer-plotted from tabular intensi t;y data with 
a Ca1com 565 plotter driven by an IBM 1620 computer 
u~1ing a Fortran II-D program. 
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Figure 12. Proposed Fragmentation Pattern of 
6-Hydroxynicotinic Acid Under 
Electron Impact 
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CO and CO at the 6 position of the pyridine ring form :Lone; 
of m/e 94 and m/e 66. The ion m/e 66 could also be formcc:~ 
by successive loss of CO at the 6-posi tion of the p;yr:'Ld:i_nG 
ring to form ion m/e 111, OH to form ion m/e 9L+ and CO tc 
form ion m/e, .. 66. The ion m/e 66 can be further cleaved D.1j 
the C-N bond, and then could either loDc 
ion m/e 39 or lose -C=H to form an ion m/e <I or rea.rr1:1nc,::: 
NH 
to ion 1,H and then lose C-CECH to form an ion m/e 2B, 
The ultraviolet spectra of the unknown compound and 
authentic 6-hydroxynicotinic acid in water 1 1 N HCl and 
1 N NaOH solution are given in Figure 13. Both compounds 
have two identical maximum UV absorption peaks at 296 m 
and 254 mµ in the water solution. The absorption maxima 
at 254 mµ and 295 mµ of both compounds are shifted to 
258 mµ when measured in 1 N HCl, and are shifted to 
265 mµ when measured in 1 N NaOH solution. Figure 14 
shows the infrared absorption spectra of unknown (upper 
spectrum) and 6-hydroxyriicotinic acid in KBr pellet. Both 
compounds have identical very broad bonded·OH stretching 
absorption in the region of 3300 to 2500 cm- 1 ~3.0-4.0 µ), 
and strong -CO absorption at 1420 cm- 1 (7 .O µ) \ind 
1160 cm- 1 (8.0 µ). 
In summary, these methods confirmed the idfntifica-
tion of the unknown as 6-hydroxynicotinic acid.' 
The finding of urinary 6-hydroxynicotinic acid sug-
gested that the corresponding 6-hydroxy derivative might 
also be formed from nicotinamide in .the rat. In fact, 
Figure 13. Ultraviolet Absorption Spectra of 
Authentic 6-Hydroxynicotinic 
Acid and the Unknown Isolated. From 
the Urine of Nicotinic Acid 
Injected Rats 
These spectra were measured using a 
Beckman D.B. Spectrophotometer. Compound 
dissolved in water 
in 1 N HCl --------. in 1 N NaUiJ_,_,_,_ 
A, authentic 6-hydroxynicotinic acid; 
B~ unknown compound. 
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E' JA.. Infrared Spectra of Authent 
6-Hydroxynicotinic Acid 
Unknown Compound Isolated 
the Urine of Nicotinic i~ 
Injected Rats 
The spectra were determined wi 
Perkin-Elmer 457 Grating Infrared 
photometer in a KBr pellet prep 
I 
T~i crosampling Kit. 6-Hydroxynic c 
r lower 3pectrum); Unknown Compound upfY?:t 
spectrum) o 
1: (- ' 
... ~ -- "' ·,- -0- -0- ...()- -0-
thin layer chromatography and high volta[:;e paper elec o--
phoresis of urine from rats injected with 500 mg/kg 
nicotinamide-7-14c revealed a new compound which was 
isolated from pooled 24 hours urines of three rats by ion 
exchange chromatography. Figure 15 shows the elution pat-
tern obtained when this urine was applied to a Dowex-50-H'f .. 
column and eluted with water. The first radioactive peak 
1 contained a mixture of unknown and N =methyl-2-pyridone-5-
Carboxamide. Further chromatography of this peak of' 
Dowex-1-formate using water as the eluting solvent pro-
duced two peaks (Figure 16). Peak I contained the 
pyridone contaminated with a small amount of the unknown 
and peak II contained the unknown conta .. minated with a 
srn.all amount of pyridone o The pyridone was separated by 
pF.1per chromatography i.n n-butanol saturated with 3% 
a. The unknown was eluted from the paper and re-
tallized from hot water. 
Figure 1? shows a comparison of the ultraviolet 
sorption spectra of authentic 6-hydroxynicotinamide (.A) 
e.nd isolated material in distilled water~ 1 N HCl and 
1 N NaOH solution. Both compounds have two absorption 
maxima at 295 mµ and 260 mµ,in water and in 1 J'-'ll'if HCl so 
tion, however, in 1 N NaOH solution both peaks were 
shifted to 270 mµ and the extinction coefficient is 
increase do 
The infrared spectra of 6-hydroxynicotinamide (upper 
spectrum) and isolated compound (lower spectrum) are shown 
Figure 15. I:solation of Unknown 1"1etaboli te ]'rom the-:! 
Urine of Nicotinamide Injected Rats 
Ten ml of a water solution of urine 
solids was placed on a 2. 5 x 20 cm column of 
Dowex-50 Hi-. The column was eluted v,ri th. water 
and 10 ml fractions were collected. Radioac-
tivity was determined on 0.1 ml aliquots by 
liquid scintillation counting and the 
absorbance at ~~90 mu measured with a Beckman DU 
spectrophotometer. Radioactive peak I contained 
., 
a mixture of N..L -methyl-2-pyridone-5-carboxamide 
and the unknown compoundo 1rubes 34-1+3 were 
pooled and concentrated to 15 ml under vacuum. 
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Figure 16. Dowex-1-Formate Column Chromatographic 
Separation of Radioactive Peak I From 
Figure 15 
The solution obtained from Figure 15 was 
applied to a 2o 5 x 20 cm Dowex-1 formate columno 
The column was eluted with water, 10 ml frac-
tions were collected and the radioactivity and 
absorbency measured as above. Peak I: 
N'-methyl-2-pyridone-5-carboxamide contaiminated 
with a small amount of the unknown compound. 
Peak II: The unknown contaminated with a 
small amount of pyridone. 
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Figure 17. Ultraviolet Spectra of A, Authentic 
6-Hydroxynicotinamide and B, Unknown 
The material isolated from the urine 
of nicotinamide injected rats; measured using 
a Bechman D.B. spectrophotomer. Compound 
dissolved in water 
in J_ N HC J. _;.;:...-.~-~-- __ ; in 1 N NaOH 
-·-··-·-
92 
• I " a.I QI i \ 
. \ 
Cl7 0.7 I I \ 
I 
Q6 
. Q6 \ :f, . 
Q5 I \ Q5 \ • I I Q4 I \ i Q4 \ i \ ... I ti \ • c Q3 ..• c 0.3 J/ 
J• 
0.2 
0.1 0.1 
220 260 300 220 260 300 
l l•J'I u.,.. 
93 
in Figure 18. The strong absorption at 3300-3L~OO cnr 1 
indicates the presence of -NH2 or -OH group, the strong 
absorption between 1600-1700 cm- 1 indicates a -CO group. 
Figure 19 shows the mass spectra of 6-hydroxynicotinamide 
(upper spectrum) and the unknown. Both compounds have a 
molecular ion of m/e 138 and fragment ion of m/e 122, 
110, 94, 66, 41, 39, and 28. The proposed fragmentation 
pattern of these compounds is shown in Figure 20. The 
parent peak is 138. Loss of -NH2 to gives B. (m/e 122). 
Further loss of -CO and CO from the 6-position of the 
pyridine ring would result in ion C (m/e 94) and ion D 
(m/e 66). Ion D also could be formed by successive loss 
of -CO (at the 6 position of the pyridine ring) to form 
ion D (m/e 66). Ion D can be further cleaved at the C-N 
bond to form ion G which can either lose H-C=N to form ion 
• 
K (m/e 39) or C = CH to form ion H (m/e 41) or rearrange to 
ion I followed by loss of C - C = C to form ion J (m/e 28). 
It is known that 6-hydroxynicotinic acid is a 
bacterial metabolite of nicotinic acid (150). In order to 
determine whether the 6-hydroxy derivatives of nicotinic 
acid and amide are formed by the intestinal flora in the 
rats'tissues, germ free rats were used. Following injec-
tion with 500 mg per kg or 5 mg per kg of nicotinic acid 
or nicotinamide into germ free rats, the urines were sub-
jected to Dowex-50 chromatography. The first radioactive 
peak eluted with water was chromatographed from the urine 
of rats injected high doses of nicotinamide. Two 
Figure 12>. Infrared Spectra of Authentic 
6-H:ydroxynicotinamide (Upper 
Spectrum) and the Unknown Compound 
Isolated From the Urine of Nicotina-
mide Injected Rats. 
Spectra were determined with a Perkin-
Elmer 457 Grating Infrared Spectrophotometer 
in a KBr pellet prepared with a Microsampl:Lng 
Kit. 
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Figure l9o Mass Spectra of Authentic. 
6-Hydroxynicotinamide and the 
Compound Isolated From the Urine 
of Nicotinamide Injected Rats 
Mass spectra were determined using 
the prototype (146) of the LKB-9000 gas 
chromatograph-mass spectrometer·using the 
direct inlet probeo The ion source temp= 
erature was 310°c, ionization current was 
65 µamps~ electron energy was 70 eVo and 
acceleration voltage was 3o5 volts. The 
mass spectra were computer-plotted from 
tabular intensity data with a CalCom 565 
plotter driven by an IBM 1620 computer 
using a Fortran II-D programo 
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Figure 20. Proposed Fragmentation Pattern of 
6-Hydroxynicotinamide 
:M* = r1etaslable ion. 
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radioactive peaks were observedo The first peak was 
6-bydroxynicotinamideo In order to further establish the 
identity of these compounds 9 they were eluted with water 
from the paper, 40 mg and 20 mg of carrier 9 respectively, 
were added and the compounds were recrystallized five 
times. As shown in Table IV 9 after the second recrystal-
lization, the specific activity of both compounds 
remained essentially constanto Therefore~ 6-
hydroxynicotina;mide and 6-bydroxynicotinic acid are prod-
ucts of metabolism in rat tissue and are not products of 
intestinal flora. 
Table V shows the comparison of the excretion of 14c 
in urine and expired 14co2 from germ free and normal rats 
treated with nicotinic .acid-7-14c and nicotinamide-7-14c. 
Table VI shows the distribution of radioactivity among the 
urinary metabolites following the injection 5 mg or 500 mg 
per kg of nicotinamide-7-14c or nicotinic acid-7-14c into 
germ free ratso These data from germ free rats are simi-
lar to those obtained from normal rats, with the exception 
that in germ free rats there was no detectable radioactive 
carbon dioxide from injected nicotinamide and nicotinic 
1 
acid-7-14c. This suggests that the formation of radio-
active carbon dioxide from injected nicotinamide and 
· t' · 'd 7 14c · d t th t b 1· f th nico 1n1c aci - = · is ue o e me a o ism o e 
intestinal flora and not to metabolism by the rats tissue. 
gure 21. Paper Strip Counter Recording of the 
Descending J?aper Chromatogram ]:Prom a 
Sample of Germ :8.,ree Rat Urine After 
Dovrnx-50-H Column Chromatography 
The Paper Chromato0;ram was developed 
:n-butanol saturated with 3% ammonia solutior, o 
The radioactive peak was iclentifi ed by 
comparison 1·11ith an authentic sample on 
:3ame chromatogram. 
6-Hydroxynicotinamide 
n 
6-Hydroxynicotinic Acid 
I 
N'-Methyl-2-Pyridone-
5-Carboxamide 
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TABLE IV 
RECRYSTALLIZATION OF URINARY RADIOACTIVE UNKNOWN METABOLITES 
OF GERM FREE RATS WITH AUTHENTIC CARRIER 
103 
Specific Activity Following 
Recrysta.11.ization (CPM/mg) 
Number Carrier 2nd 3rd 4th 5th 
-·~-
I 6-Hydroxynicotinic acid 107 119 119 102 
II 6-Hydroxyn1cot1namide 165 136 149 155 
TABLE V 
A COMPARISON OF THE EXCRETION OF RADIOACTIVITY IN THE URINE AND 
EXPIRED co2 OF GERM FREE AND NORMAL RATS 24 HOURS Ab'TfR 
INTRAPERITONEAL ADMINISTRATION OF N~COTINIC ACID-7-lLJ·c 
AND NICOTINAMIDE=7-l C 
Type of Rat 
germ free 
germ :free 
normal 
normal 
germ free 
normal 
11C)T(i1c3.1. 
Treatment 
Nicotinamide 
500 mg/kg 
5 mg/kg 
500 mg/kg 
5 mg/kg 
Nicotinic Acid 
500 mg/kg 
5 mg/kg 
500 mg/kg 
5 mg/kg 
Radioactivity 
Excreted :in the 
Urine(% of dose) 
7605 
54,3 
70o4 
68.5 
Expired Rad:loactive C02 
(% of dose) 
o.o 
L2 
4.7 
TABLE VI \ \ 
THE DISTRIBUTION OF RAD]OACTIVITY IN THE. URINARY METABOLITES 
OF GERM FREE RATS FOLLOWING THE ADMINISTRAT~ON OF 
NICOTJNAM])E-7-14c AND NICOTINIC ACID-7-1 C 
(PER CENT OF INJECTED DOSE)"' 
nicotinic acid nicotinarnide 
Compound 500 mg/kg 5 mg/kg 500 mg/kg 5 mg/kg 
1 N -methylnicot1nam1de 1.4 8.4 8.3 45.1 
6-Hydroxyn1cot1n1c acid o.6 1.0 o.4 o.4 
Nicotinuric acid 17.3 :?4.9 9.8 0.5 
Nicotinic acid 56.8 9.9 15.0 0.5 
Nico tinam1.de=N-oxide 2.6 1.3 8.o 3.2 
6=Hydroxynicot1narn1de trace 0.2 o.6 0.5 
N9=methyl=2=pyridone-
5-carboxamide 0.2 1.0 o.6 4.5 
Nv-methyl-4-pyridone-
?-carboxamide trace o.6 0.9 :?. .o 
Nicotinamide L6 O.? ;,8.2 5.9 
*Each figure in this table is the average of two rats. 
CHAPTER VI 
SU1'11'1ARY 
· Nicotinic acid is rapidly incorporated into NAD-:-
within a short time after intraportal injection of 
nicotinic acid into normal and hypophysectomized ratso 
The newly formed NAD'V" is also rap.idly degraded probably 
.• 
by NADase into nicotinamideo The formation of nicotina-
mide increases withan increasing dose of injected nico-
tinic acido This indicates that NADase probably plays a 
key role in control of the concentration of NAD? in liver. 
In the experiment ':l.n which nicotinami.de was in~iected 9 the 
nicotinamide was ~;apidly incorporated into N1-
methylnicotinamide immediately after injection and only a 
small amount of NADv was formed wi thi.n 60 minutes :in 
hypophysectom1zed and normal ratso 
The ~ate of excretion of nicotinic acid and nicotina-
mide in the urine followed the intraperitoneal injection 
of nicotinamide and nicotinic acid i.n hypophysectomized 
rats is slower than that in normal ratso Hypophysectomized 
also excrete smaller amounts of N1-methynicotinamide and 
nicotinuric acid within 24 hours after injection of nico= 
tinic acid and nicotinamide than do normal ratso This 
finding provides a possible explanation for the increase 
lC.6 
107 
in the magnitude and duration of the elevation in rat 
liver NAD following the administration of nicotinam:i.de and 
nicotinic acid to hypophysectomized ratso The excretion 
of nicotinic acid in the urine was greatly increased by 
injection of a large dose of nicotinamideo Two new 
urinary nicotinamid.e metabolites have been isolated and 
identified by spectrometric methods as 6-hydroxynicotinic 
acid and 6-hydroxynicotinamide. Studies with germ free 
rats indicate that these new metabolites are formed by 
tissue metabolism and not by metabolism of the intestinal 
flora. The formation of respiratory 14co 2 following 
intraperitoneal injection of nicotinamide-7-14c and 
· t · · · d 7 14c · t 1 t h' h · ·1 nico 1n1c aci - - in o norma ra s w 1c was previous_y 
repor-ted is not due to the metabolism of rat tissue but to 
the metabolism of intestinal flora. 
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